Development of a Composite Layered Double Hydroxide-liposomal System for Gene Delivery by Dong, Haiyan
  
 
 
 
Development of a Composite Layered Double Hydroxide-liposomal 
System for Gene Delivery 
Haiyan Dong 
ME, BS 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2014 
 
Australian Institute for Bioengineering and Nanotechnology 
 
ii 
Abstract 
In recent years, gene therapy has attracted much attention in treating a wide range of 
severe diseases, including cancers. Unfortunately, naked genetic materials are rapidly 
degraded by the ubiquitous nucleases in the body and their negative charge property 
hinders crossing cell membrane to the cytoplasm. Thus, an efficient delivery system is 
urgently sought for desired gene therapeutic efficacy. 
Up to date, a wide variety of vectors have been examined for gene delivery, including viral 
and non-viral ones. Non-viral vectors, including polymers, cell penetrating peptides 
(CPPs), liposomes, and inorganic nanoparticles (NPs), are clinically promising due to their 
safety. It is well known that every delivery system has its own unique merits and inherent 
shortfalls, hence hybrid delivery systems are expected to merge their advantages while 
avoid their drawbacks. 
Inorganic layered double hydroxide (LDH) acts as an excellent drug/gene delivery vehicle 
due to its protection to the loaded drugs/genes and efficient cellular uptake by various 
mammalian cells. However, aggregation of LDH NPs in serum or culture medium limits the 
effective application in vivo. On the other hand, liposome is a promising lipid-based system 
which can protect the hydrophilic genes/drugs in the aqueous core or hydrophobic drugs 
between the lipid bilayers, and it is colloidally stable in the circulatory blood flow. 
Unfortunately, its disadvantages are also obvious, such as low transfection efficiency and 
inefficient endosome escape. 
This PhD project aims to develop a hybridised delivery system by forming small LDH 
(sLDH)-liposome composites. Considering encapsulating LDH NPs in the vesicles of lipid 
bilayers, small Mg-Al-LDH NPs were first prepared by a non-aqueous method with the Z-
average diameter size of ~ 40 nm. This method requires co-precipitation of magnesium 
and aluminium nitrate solution with sodium hydroxide in methanol, followed by LDH slurry 
collection and re-suspension in methanol. The methanol suspension is then heated in an 
autoclave, followed by separation via centrifugation and thorough washing with deionised 
water. The NPs are finally dispersed in deionised water into homogeneous aqueous 
suspension after 4-6 day standing at room temperature. The prepared sLDH NPs have the 
Z-average size of 35-50 nm, the number-average size of 14-30 nm and the polydispersity 
index (PdI) of 0.19-0.25, with the colloidal suspension stable for at least 1 month when 
stored at fridge (2-8 °C) or ambient (22-25 °C) temperature. 
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Engineered sLDH with the Z-average size of ~40 nm and normal LDH with the Z-average 
size of ~100 nm (large LDH, denoted as L-LDH in this thesis) were then compared in 
transfection efficiency to human colon cancer HCT-116 cells. Using fluorescein 
Isothiocyanate (FITC) to label LDH NPs and as a model anionic drug (where FITC is 
intercalated in the interlayers of LDH NPs), we found that 40 nm sLDH and 100 nm L-LDH 
have the similar cellular uptake rate based on the equivalent particle number 
concentration, which means in the size range of 35 to 100 nm, LDH NP size does not 
significantly affect the cellular uptake rate. Note worthily, a critical particle number 
concentration was found for both sLDH and L-LDH, below which the cellular uptake is in 
linear proportion to the concentration, while above which, the cellular uptake is not further 
improved. 
When delivering genetic materials to cancer cells (where DNA is adsorbed on the surfaces 
of LDH NPs), sLDH is far superior to L-LDH at low LDH:DNA mass ratio (e.g. 5:1). This is 
mainly attributed to full loading of DNA by sLDH and higher sLDH particle number 
concentration. At the high mass ratio (40:1), where both sLDH and L-LDH can completely 
bind and protect DNA, sLDHs are able to transport 2-fold DNA to the cells just because of 
the higher sLDH particle concentration.  
Finally, sLDH-liposome composites were prepared by the hydration of freeze-dried matrix 
(HFDM) method. This composite system exhibits good colloidal stability both in water and 
in cell culture medium, with the Z-average particle size ~ 200 nm, which is appropriate for 
cellular uptake. It is also proved for the composite system to completely bind/protect DNA 
at LDH:DNA mass ratio = 20:1, no matter how DNA is loaded in the composite system. 
About 3-time higher efficiency is observed in delivery of DNA to HCT-116 cells by the 
sLDH-liposome composite system compared to sLDH only.  
In general, the sLDH-liposome composite system shows higher cellular delivery efficiency 
than either sLDH or liposome only, good colloidal stability and low cytotoxicity, so it could 
be a promising gene delivery system. 
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Chapter 1 Introduction 
1.1 Background 
Gene therapy uses genetic material(s) as drug(s) to treat a wide range of severe diseases, 
genetic disorder/deficiency related diseases, or cancers. A growing body of evidences 
have proved the effectiveness and efficacy of gene therapy in breast cancer, colon cancer, 
prostate cancer, cardiovascular disease, immune deficiencies, neurological disorders, 
Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Unfortunately, the 
success of gene therapy relies on a safe and efficient vector because of various 
extracellular and intracellular barriers for naked genetic drugs. 
So far, a broad spectrum of vectors has been developed for gene delivery, including viral 
and non-viral ones. Viral vectors are highly efficient due to their native properties, but they 
are suffering from safety concerns. Non-viral vectors are generally categorised into organic 
and inorganic ones. Organic vectors include polymers, liposomes, cell penetrating 
peptides, and inorganic vectors involve metal and metal oxide nanoparticles (NPs), carbon 
nanotubes, mesoporous silica NPs, calcium phosphate NPs, and layered double hydroxide 
(LDH) NPs. Each pure system has its own advantages along with its drawbacks, so 
hybridisation systems have been widely developed and proved to merge the merits from 
two or more worlds, while overcoming their limitations.  
1.2 Research hypothesis and specific objectives  
Inorganic layered double hydroxide (LDH) nanoparticles (NPs) have been well developed 
for drug and gene delivery. LDH NPs are easily prepared in the lab by co-precipitation of 
mixed salt solution with certain ratio of sodium hydroxide followed by purification, with 
tailored particle size, high loading capacity and protection for the payload. They also have 
beneficial properties such as low cytotoxicity, efficient cellular uptake, controlled cargo 
release and endosome escape. Unfortunately, the aggregation of LDH NPs in serum/blood 
circulation is a big hurdle for its in vivo application.  
On the other hand, liposomes are colloidally stable in blood circulation especially after 
modified by poly(ethylene glycol) (PEG), and they are the most biocompatible organic 
delivery vehicles for genes and drugs because it consists of cell membrane constitutes 
lipids, protects hydrophilic drugs and genetic materials in the aqueous core of liposomal 
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vesicles, hydrophobic drugs between the lipid bilayers. Unfortunately, inefficient endosome 
escape is a crucial drawback for liposomes as an excellent delivery system.  
Therefore, we hypothesised to develop a hybridised LDH-liposome composite system by 
combining the advantages of LDH NPs for high transfection efficiency, low toxicity, good 
safety, rapid endosome escape, efficient and controlled release of the payload, and 
liposomes for good colloidal stability, while avoiding their downsides by LDH NPs for 
aggregation, and liposomes for inefficient endosome escape and cargo release.  
To achieve the overall aim stated above, the specific stage-by-stage objectives for this 
project are:  
[1] to develop a procedure for preparing small LDH (sLDH) NPs (Z-average 
diameter size ~ 30 to 50 nm) i.e. ≈1/3 to 1/2 the size of normal LDH NPs (Z-
average size ~ 100 - 110 nm, denoted as large LDH, L-LDH in this thesis, 
compared to sLDH), which is appropriate to be encapsulated inside the 
liposomal vesicles;  
[2] to compare the gene loading capacity and delivery efficiency between sLDH 
and L-LDH NPs, and explore how the LDH particle size affects the cellular 
delivery;  
[3] to prepare LDH-liposome composite and then assess its suspension stability, 
gene loading capacity, and gene delivery efficiency.  
1.3 Thesis outline 
Following the specified objectives, the whole thesis is composed of seven chapters and 
one appendix; each being briefly introduced below.  
Chapter 1 is the general introduction. Here, the necessity of developing gene delivery 
vectors is stated, and then the research hypothesis and specific objectives are presented, 
followed by the detail thesis structure.  
Chapter 2 reviews the recent advances in gene delivery systems, including categories of 
vectors and their advantages along with drawbacks, strategies to overcome the drawbacks 
and improve/enhance gene delivery efficiency. Among them, hybridisation of two or more 
pure systems for a multifunctional composite system is a new research direction which 
merges the merits from all separate systems, while overcomes their limitations. This 
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chapter ends with a summary for these delivery systems and further brings forward the 
project hypothesis.  
Chapter 3 is a summary for the materials and the general methods used in this thesis, 
including some characterisation techniques.  
Chapter 4 states the synthesis of small LDH nanoparticles (NPs) by a non-aqueous co-
precipitation method, followed by hydrothermal treatment and washing, natural dispersion. 
Finally obtained well-dispersed sLDH NPs suspension possesses a Z-average diameter 
size ~ 40 nm with narrow size distribution. A wide range of parameters are examined to 
explore their effects on sLDH particle size and suspension dispersion. Moreover, the 
mechanism for sLDH NPs formation via non-aqueous co-precipitation method is proposed. 
Chapter 5 compares the cellular delivery efficiency of small LDH (sLDH) and large LDH (L-
LDH) NPs. Particle size in the range of 35 ~ 100 nm does not obviously affect the cellular 
uptake rate of LDH NPs, while sLDH NPs show improved gene delivery efficiency because 
they possess larger specific surface area than L-LDH NPs. The gene materials are mainly 
adsorbed on the surface of LDH NPs via electrostatic interaction. Meanwhile, at the same 
mass ratio to genetic materials, sLDH NP suspension exhibits much higher particle 
number concentration, which is proved to be critical for cellular uptake.  
Chapter 6 examines the suspension stability, nucleic acid loading, and cellular delivery 
efficiency of the LDH-liposome composite system prepared by the hydration of freeze-
dried matrix (HFDM) method. LDH-liposome composites possess narrow size distribution 
with Z-average diameter size ~ 200 nm, which is proper for cellular uptake and is 
determined to be stable in serum. The nucleic acids are fully immobilised by the composite 
system no matter how nucleic acids are loaded in the system. The sLDH-liposome 
composite system shows 2-3 times improved cellular delivery efficiency than sLDH, while 
L-LDH-liposome exhibit no difference from L-LDH only, which might imply encapsulation of 
sLDH NPs inside liposomal vesicles, but not for L-LDH NPs.  
Chapter 7 gives the final conclusions and the future directions following this thesis. More 
efforts could be dedicated for investigating the mechanisms for sLDH-liposome composite 
formation, which would guide to develop new method(s) or formulations to further improve 
the encapsulation efficiency of sLDH in the composite. The cellular uptake behaviour and 
endosome escape pathway of this composite system could also be explored; this would 
pave a way for further enhancing the cellular delivery. Following modification of the 
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composite system such as PEGylation or linking targeting ligands could be considered for 
better stability in blood circulation and targeting delivery of genetic materials. Combination 
therapy could be developed for the new composite system, loading hydrophilic anionic 
drugs or genes by LDH, and carrying hydrophobic drugs by liposomes. Functional gene 
therapeutic materials such as functional siRNA could be attempted for the practical 
application of this new delivery system. 
 
PhD thesis: Development of a Composite Layered Double Hydroxide-liposomal System for Gene Delivery 
5 
Chapter 2 Literature Review 
2.1 Introduction 
Although gene therapy has proved to be superior to traditional chemotherapy for some 
severe diseases, cancers, and genetic deficiency related diseases, its therapeutic 
efficiency is highly dependent on a safe and efficient delivery vehicle. Vectors developed 
so far are divided into two major categories, viral vectors and non-viral vectors. 
Generally, viral vectors can deliver genetic materials into the targeted cells with high 
transfection efficiency due to their naturally evolved property, overcoming cellular barriers 
easily. Normal viral vectors include adenovirus, retrovirus, and lentivirus (Figure 2-1). 
 
Figure 2-1 Viral vectors for gene therapy, reproduced from Ref. 1 
 
Figure 2-2 Vectors used in gene clinical trials, The journal of Gene Medicine ©2014 John 
Wiley and Sons Ltd, www.wiley.co.uk/genmed/clinical 
Moreover, most of the approved gene therapy clinical trials are using viral vectors (Figure 
2-2). However, they have major drawbacks. Viruses can be cleared in the blood-stream by 
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pre-existing antibodies and can activate complement or coagulation factors. They can also 
induce neutralising antibody responses that prevent repeated administration. Dys-
regulation of gene expression in the target cell by insertion is a major safety issue, and 
some viruses integrate only in dividing cells.2 Substantial safety concerns are also resulted 
from their high risk for immunogenic responses and mutagenicity, viral vectors therefore 
should be restricted strictly in the clinical practice.  
Non-viral vectors are good alternatives to viral ones for their safety, simplicity and capacity 
for packing large nucleic acids. They are studied extensively in recent decades as they are 
non-immunogenic, non-mutagenic, and easy for scale-up production. Generally, non-viral 
vectors can be categorised into organic and inorganic systems.  
2.2 Organic vectors with a wide range of variety 
Normally used organic materials for gene delivery include polymers, dendrimers, 
liposomes, cell penetrating peptides, etc.  
2.2.1 Polymers 
Polymers are the most investigated organic materials for drug/gene delivery. The most 
widely used polymers such as PLGA (poly(lactide-co-glycolide) or poly(lactic-co-glycolic 
acid)), PEI (polyethyleneimine), PEG (polyethylene glycol), chitosan, and their hybrids, had 
been applied for delivering a broad range of drugs, microRNA, and small interfering RNA 
(siRNA), as reviewed by Devulapally and Paulmurugan recently.3  
PLGA is a biodegradable and biocompatible polymer, which has been approved by FDA 
(Food and Drug Administration). PLGA has been widely used for drug delivery due to its 
low systematic toxicity and immune-modulatory effects, because it is rapidly hydrolysed in 
the body to biodegradable monomers lactic acid and glycolic acid (Figure 2-3).3 Most 
chemotherapeutic drugs are also toxic to the healthy cells, tissues, and organs, but by 
encapsulating the drugs using PLGA-based NPs, the adverse effects of chemotherapeutic 
drugs can be avoided.  
PEGylated PLGA nanoparticles (NPs) are one of the most popular polymer hybrids for 
drug and gene delivery. By PEGylation, the drugs/genes encapsulation, complexes 
circulation time, and bioavailability are improved, because PLGA polymers are 
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hydrophobic, but PEG is well-established hydrophilic. Hydrophilic PEG also protects the 
complexes from the immune clearance. 
 
Figure 2-3 Hydrolysis of PLGA in the body into biodegradable lactic acid and glycolic acid, 
reproduced from Ref. 3 
Another widely studied polymer is PEI, which is also considered with highest gene 
transfection efficiency. PEI was firstly used as gene delivery in 1995 by Boussif et al.4 It is 
an organic macromolecule with the highest cationic-charge-density potential. This property 
provides PEI to condense and compact DNA into tight complexes, so that DNA is 
protected from degradation. The amino group (-NH-) in the PEI chain (Figure 2-4) can be 
protonated, which renders PEI a substantial buffering capacity at any virtual pH, provides 
PEI-DNA complexes an escape mechanism via endosomal/lysosomal swelling and 
rupture, so called ‘proton sponge’ effect. Figure 2-4 shows the diagram for linear and 
branched PEI structures, formation of PEI-gene materials complexes, surface 
modifications of PEI-based complexes for targeted delivery. Boussif et al. also found the 
cytotoxicity of PEI was low and only noted well above the required concentrations for 
optimal transfection. Since then, PEI has been widely used as gene delivery vectors.5-9 
After the superiority of siRNA has been recognised, PEI has also been quickly used for 
siRNA delivery.10-12 
Cytoplasmic delivery of siRNA after endocytosis of the particles is achieved through the 
‘proton sponge’ effect of PEI, which results in endosomal rupture. While any rupture or 
leakage of the endosomal or lysosomal membrane will lead to cell stress, inflammasome 
activation associated with apoptosis, which precludes prolonged use of PEI in vivo. In 
general, PEI-RNA complexes accumulate in the liver, lung, spleen and kidney, limiting 
their utility for other tissues. 
Chitosan is another commonly used polymer for drug/gene delivery, which is a positively 
charged, biodegradable, linear polysaccharide composed of β-(1-4)-linked D-glucosamine 
(deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit) (Figure 2-5). The primary 
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amines on it become protonated at pH<8.5, which is beneficial for binding nucleic acids 
and endosomal escape of chitosan-nucleic acid complexes through ‘proton-sponge’ effect.  
 
Figure 2-4 Schematic illustration of PEI structures, complex formation, and surface 
modifications, reproduced from Ref. 13 
 
Figure 2-5 Chemical structure of chitosan 
Chitosan was introduced for siRNA delivery by Alpar’s group and Howard’s group because 
of its low toxicity, biodegradability and biocompatibility.14, 15 Howard’s group also found that 
the physicochemical properties (size, zeta potential, morphology and complex stability) are 
strongly dependent on the chitosan molecular weight and degree of deacetylation, which 
affect the in vitro gene silencing of chitosan/siRNA nanoparticles.16  
Recently, combination of polymeric materials has been intensively explored for improved 
therapeutic efficacy. For instance, MPEG-PLA-PAE copolymer (methoxy PEG-PLA-poly(β-
amino ester)) was found to be more stable in plasma than MPEG-PLA micelles, with 
improved cellular uptake by MCF-7 cells, longer circulation time, and enhanced tumour 
growth inhibition with anticancer drug curcumin.17 It has also been reported that hy-PEI-
PCL-mPEG copolymers (mono-methoxyl-poly(ethylene glycol)-block-poly(ɛ-caprolactone) 
(mPEG-PCL) modified hyperbranched PEI copolymers) exhibits higher stability and 
reduced zeta-potential for siRNA polyplexes.18  
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Besides biodegradability of polymeric materials, which saves post-treatment clearance of 
polymeric NP waste, ease of surface modification is another superior property for 
polymeric NP drug delivery system, such as addition of pH/thermal/GSH (glutathione) 
sensitive linker for external stimuli cargo release or addition of targeting ligand for active 
targeting delivery. Modification of polymeric nanocarrriers by RGD (Arg-Gly-Asp)- and 
NGR (Asn-Gly-Arg)-based oligopeptides/HIV-1 Tat peptides/folate/ hyaluronic acid can 
realise the active targeting to tumour blood vessels.20-23 
 
Figure 2-6 Schematic illustration of charge reversal of dual-responsive polymer micelles 
for tumour extracellular matrix and intracellular GSH-triggered drug release, reproduced 
from Ref. 19 
More complicated delivery systems have been designed by combining external stimuli 
release with active targeting. For example, Guo et al.19 developed dual-responsive 
copolymer micelles with disulphide linker, sheddable PEI and targeting ligand folic acid 
(FA). The system exhibits prolonged circulation time because of the originally negatively 
charged surface, and it is ultrasensitive to the tumour extracellular pH with reverse charge 
property, which greatly enhances cellular uptake via electrostatic interactions. At the same 
time, the active targeting property of the micelles with FA further improves the selective 
uptake by the cancer cells. Once the micelles escape from endosome/lysosome, the 
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disulphide linkage can be cleaved by GSH (glutathione) in the cytoplasm, causing rapid 
release of encapsulated agent to the nuclei. The charge reversal of this system in tumour 
extracellular pH condition, and the cleavage of disulphide linkage causing encapsulated 
agent release are illustrated in Figure 2-6.  
Although polymers have shown their capability and advantages in drug/gene delivery 
because of biodegradability, protection of drugs/genes, accumulation of polymeric NP-
drug/gene complexes in tumour sites via enhanced permeability and retention (EPR) 
effect, ease of surface modification for active targeting, the cytotoxicity of polymeric NP still 
needs further investigation and strategies to alleviate the toxic property of polymeric NP 
are still needed to be explored. Schäfer et al.24 assessed a broad range of lipids modified 
low molecular weight PEI25 based nucleic acid polyplexes and found that introduction of 
negative, rigid lipids into polyplexes leads to increased transfection, which is attributed to 
the enhancement of clathrin-dependent internalisation. Moreover, introduction of liposome 
to polyplexes decreases the toxicity of polyplexes.  
2.2.2 Dendrimers 
Dendrimers are a class of globular nano-sized (1-100 nm) macromolecules with a 
particular ‘tree-like’ highly branched three-dimensional architecture. Different from linear 
polymers, dendrimers possess precisely controlled architecture with tailor-made surface 
groups, which can be finely tuned and modified. Figure 2-7 shows the types and chemical 
structures of different dendrimers. Of them, the most used dendrimers are PAMAM 
(polyamidoamine) dendrimer and PPI (polypropylenimine) dendrimer.  
Dendrimers can be applied in gene delivery field because they are able to condense and 
compact gene materials to form polyplexes/dendriplexes, so as to protect genetic 
materials. Triethanolamine (TEA)-core PAMAM denderimer was reported to successfully 
deliver siRNA to a prostate cancer model in vitro and in vivo, resulting in potent gene 
silencing and notable anticancer effect.25  
Various modifications have been explored by researchers to improve the transfection 
efficiency of dendrimers while reduce the cytotoxicity. It has been reported that disulphide 
cross-linked PAMAM dendrimers show improved transfection efficiency and low 
cytotoxicity, which is comparable to commercial branched PEI.26 Fluorinated PPI 
dendrimers have comparable or superior transfection efficacies to six representative 
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transfection reagents. Moreover, these fluorinated PPI dendrimers exhibit low cytotoxicity 
on the transfected cells because they achieve excellent transfection at extremely low N/P 
ratios.27, 28 Oligoamine linker modified PAMAM dendrimers exhibit significantly improved 
transfection with low cytotoxicity, and the following siRNA delivery results in ~73% 
suppression of the target gene.29 
 
Figure 2-7 Different types of dendrimers, reproduced from Ref. 30 
Conjugation with peptide or other NPs has also been explored for improved therapeutic 
efficacy or for target delivery. For example, arginine, cyclodextrin, PEG conjugated 
dendrimers showed enhanced transfection efficiency.31-35 Peptide conjugated dendrimers 
allow for target delivery of genetic materials.36-38 Dendrimers with entrapped gold NPs (Au 
NPs) have significantly higher transfection efficiency than dendrimers only.39  
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2.2.3 Cell-penetrating peptides (CPPs)  
Cell penetrating peptides (CPPs) are another class of organic biomolecules (mostly 
positively charged) which have been used as non-viral vectors. They are a class of short 
peptides (typically with 5-30 amino acids), which differ from other peptides with specific 
feature to enter cells via various mechanisms: energy dependent endocytosis (including 
macropinocytosis, clathrin-dependent endocytosis, caveolae/lipid raft-mediated 
endocytosis, andclathrin/caveolae-independent endocytosis) and energy independent 
direct translocation across the membrane bilayer (through toroidal/barrel-stave poremodel 
or carpet model). The CPP cell entry pathways are summarised in Figure 2-8.  
 
Figure 2-8 Cell entry pathways of cell penetrating peptides, reproduced from Ref. 40 
The positive charge property of cationic CPPs renders the spontaneous interaction and 
complexation between CPPs and gene materials, which enables autonomously cross the 
plasma membrane and then facilitates the cellular uptake. Since their discovery in 1988, 
CPPs have been widely used as vectors for siRNA,41-44 nucleic acid,45 small molecule 
therapeutic agents,46 proteins,47 QDs,48 and MRI contrast agents.49 For example, Crombez 
et al.41 designed a secondary amphipathic peptide (CADY) for siRNA delivery, and found 
CADY forms stable complexes with siRNA, with increased stability and improved cellular 
delivery. Moreover, CADY mediated siRNA delivery leads to significant knockdown of the 
target gene at both the mRNA and protein levels and the CADY is proved to be nontoxic. 
Hoyer and Neundorf44 demonstrated that CPPs can effectively transport siRNA into HEK-
293 and MCF-7 cell lines without inducing cytotoxicity, knocking down the expression of a 
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G-protein-coupled receptor, the human neuropeptide Y Y1 receptor. The knockdown rates 
are comparable to those obtained by lipofection. This offers a potential therapy for Y1 
receptor disorder, such as osteoporosis.  
 
Figure 2-9 Cell penetrating peptide mimicking polymer for codelivery of anticancer drug 
and siRNA, reproduced from Ref. 50 
On the other hand, CPP-modified/functionalised pH-sensitive and thermally sensitive 
carriers are also extensively explored for drug delivery. For instance, Cohen et al.51 
functionalised acid-degradable polyacrylamide particles with polyarginine CPPs, and found 
improved cellular uptake by non-phagocytic cells. Walker et al.52 conjugated three different 
CPPs to a thermally responsive macromolecular carrier elastin-like polypeptide (ELP), and 
found clearly enhanced cellular uptake. 
More interestingly, Jang et al.50 synthesised a CPP mimicking conjugate of deoxycholic 
acid and low molecular weight PEI (DA3) for codelivery of anticancer drug paclitaxel and 
siRNA, and found higher target gene silencing efficiency with enhanced cancer cell growth 
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inhibition and tumour growth suppression. Figure 2-9 illustrates the complexes of DA3 with 
siRNA and paclitaxel taken up by cells via endocytosis and endocytosis independent cell 
membrane translocation, followed by enhanced inhibition of cancer cells and gene 
silencing. 
2.2.4 Liposomes 
Liposomes are artificially-made lipid bilayer vesicles, which was firstly observed and 
described by Bangham.53, 54 When Bangham and Horne were testing the institute's new 
electron microscope by adding negative stain to dry phospholipids, they noticed the 
lamellar structures formed spontaneously which can sequester solutes. Specifically, when 
lipids are exposed to excess water or in an aqueous system, the polar heads of lipids align 
towards the polar, aqueous environment, while the hydrophobic tails minimize their contact 
with water and tend to cluster together, forming vesicles. Depending on the lipid 
concentration, this biophysical interaction may result in the formation of micelles, 
liposomes, where liposomes are lipid bilayer spheres in water or solution with entrapped 
water or solution inside. Additionally, there can be some reverse micelles formed when 
lipids are exposed to the mixture of organic solvent or solution.  
 
Figure 2-10 Schematic structures of lipid molecule (A), lipid bilayer (B), multilamellar large 
vesicle (MLV, C), large unilamellar vesicle (LUV, D), micelle (E), and reverse micelle (F) 
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Liposomes can be classified into multilamellar large vesicle (MLV), large unilamellar 
vesicle (LUV) and small unilamellar vesicle (SUV) according to their particle size and 
number of lamellae. MLVs are normally hetereogeneous, with size ranging from 400 to 
3500 nm in diameter. LUVs generally range from 200 to 1000 nm with the largest 
entrapment volume and the highest encapsulation efficiency. SUVs are in the range of 25 
to 100 nm with the most uniform size distribution, which can be attained from MLVs and 
LUVs by size reduction process (such as ultrasonication, gas extrusion). Figure 2-10 
shows the schematic structures of lipid molecule, lipid bilayer, liposomes, micelles, and 
reverse micelles. 
Liposomes are composed of natural cell membrane constituents and can be re-utilised by 
the body as fuel,55 thus they are biocompatible with non- or very weak immunogenic and 
intrinsic toxicity. In the past decades, liposomes are widely used for drug delivery for their 
wide variety of compositions, reduced cytotoxicity compared to viral vectors, well-defined 
structure compared to linear polymers, narrow size distribution for cellular uptake, high 
entrapment efficiency for drugs, extended circulation lifetime by PEGylation,56, 57 
accumulation at regional sites,58 surface-associated targeting,59, 60 ease for large-scale, 
and cost-effective artificial synthesis aseptically. The evolution of liposomes are shown in 
Figure 2-11. However, liposome still faces a few stability issues. Its chemical stability is not 
high because of hydrolysis of ester bond or oxidation of unsaturated acyl chains. 
Physically, drug molecules are likely to leak from vesicles and vesicles to aggregate or 
fuse to larger particles. Furthermore, the endosomal escape mechanism of liposome via 
forming ion pairs with anionic phospholipids within the endosomal membrane,61 which is 
less efficient than the ‘proton sponge’ effect of PEI. 
Incorporation of dendrimer in liposome has been found to improve the drug entrapment 
while slow the release rate, leading to improved therapeutic efficacy.63, 64 Liposomes 
coated with synthetic pH/temperature sensitive peptides could release the contents in 
response to pH/temperature change.65 pH-sensitive polymer modified liposomes has been 
explored as antigen delivery carriers for cancer immunotherapy. The modified liposomes 
are found to be taken up efficiently by dendritic cells, and they are stable at neutral pH, but 
destabilised in response to acidic pH. With loaded ovalbumin (OVA), the tumour growth is 
significantly suppressed in mice model.66, 67 
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Figure 2-11 Evolution of liposomes. (A) Early traditional phospholipids ‘plain’ liposomes 
with water soluble drug (a) entrapped into the aqueous liposome interior and water-
insoluble drug (b) incorporated into the liposomal membrane. (B) Antibody-targeted 
immunoliposome with antibody covalently coupled (c) to the reactive phospholipids in the 
membrane, or hydrophobically anchored (d) into the liposomal membrane after preliminary 
modification with a hydrophobic moiety. (C) Long-circulating liposome grafted with a 
protective polymer (e) such as PEG, which shields the liposome surface from the 
interaction with opsonising proteins (f). (D) Long-circulating immunoliposome 
simultaneously bearing both protective polymer and antibody, which can be attached to 
the liposome surface (g) or, preferably, to the distal end of the grafted polymeric chain (h). 
(E) New-generation liposome, the surface of which can be modified (separately or 
simultaneously) by different ways. Among these modifications are: the attachment of 
protective polymer (i) or protective polymer and targeting ligand, such as antibody (j); the 
attachment/incorporation of the diagnostic label (k); the incorporation of positively charged 
lipids (l) allowing for the complexation with DNA (m); the incorporation of stimuli-sensitive 
lipids (n); the attachment of stimuli-sensitive polymer (o); the attachment of cell-penetrating 
peptide (p); the incorporation of viral components (q). In addition to a drug, liposome can 
loaded with magnetic particles (r) for magnetic targeting and/or with colloidal gold or silver 
particles (s) for electron microscopy. Reproduced from Ref. 62 
Very specifically, successful incorporation of single-stranded DNA block copolymers (DNA-
b-polypropyleneoxide, DNA-b-PPO) to the lipid bilayers of liposomes helps achieve the 
target delivery of liposomes via the specific recognition of oligonucleotides (ODNs) by 
hybridisation with their complementary strands, while the oxidation of PPO chains or the 
highly unsaturated lipids effectively mediates the release of drugs/genes loaded in 
liposome vesicles.68 Figure 2-12 shows the incorporation of DNA block copolymers (DBCs) 
to liposome vesicles, hybridisation of single-stranded DNA from DBCs with complementary 
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DNA sequence, and the light irritation triggering release of payload from liposomes. Lipid 
(monolayer/bilayer) coated other delivery materials, such as polymeric NPs, mesoporous 
silica NPs as drug delivery systems are reviewed recently by Raemdonck et al.69 These 
hybrids mainly merges the beneficial features of both materials in a single nanocarrier 
while avoid their limitations, and they are proved to be suitable for combination therapy to 
enhance therapeutic efficacy and reduce drug resistance. Lipid coated calcium phosphate 
(CaP) NPs are developed by Huang’s group for nontoxic composites with pH responsive 
cargo release and good stability in blood circulation.70, 71 
 
Figure 2-12 Schematic illustration of DNA block copolymer incorporated in liposome 
vesicle, hybridisation of single-stranded DNA from DBCs with complementary DNA 
sequence, and light irritation triggered release of payload from liposome vesicle, 
reproduced from Ref. 68  
2.2.5 Polymersomes 
Polymersomes are self-assembled polymeric vesicles, which have also been used in 
nanomedicine recently, as they can encapsulate hydrophilic compounds with the aqueous 
core and incorporate hydrophobic and amphiphilic molecules within the bilayers like 
liposomes, while they are more stable than liposomes. Figure 2-13 illustrates the 
schematic structures of liposome, polymersome and dendrimersome.  
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Figure 2-13 Schematic structures of liposome, polymersome, and dendrimersome, 
reproduced from Ref. 73 
Nahire et al.72 prepared redox sensitive and folate receptor targeted polymersomes from 
disulphide-linked copolymer PEG-S-S-PLA, and used them for encapsulating anticancer 
drugs gemcitabine and fluorouracil (5-Fu) simultaneously. They found that the 
polymersomes can release 80% of the encapsulated drugs within 20 min when incubated 
in solution with reducing agents at the cytosolic concentration level, while exhibit minimal 
release in serum levels of reducing agents. Folate-targeted polymersomes show enhanced 
uptake by folate-receptor overexpressing breast and pancreatic cancer cells and the drug 
encapsulated polymersomes show significant cytotoxicity to the cancer cells. 
As another example, Xu et al.74 prepared cross-linked polymersomes from temperature-
sensitive copolymers, and found the cross-linked polymersomes can encapsulate model 
protein with loading efficiency > 85 wt%, with remarkable stability against dilution, organic 
solvent, high salt conditions and change of temperature, while the polymersomes are 
rapidly dissociated under reducing conditions mimicking intracellular environment.  
2.2.5 Niosomes 
Niosomes are self-assembled vesicles after hydrating a mixture of single or double alkyl-
chain, non-ionic surfactant with cholesterol, which are similar to liposomes in terms of 
structure and physical properties. They can also be prepared as unilamellar and 
multilamellar vesicles. The self-assembly of non-ionic surfactant into vesicles was firstly 
observed and reported in 1979.75 Since then, they have been extensively explored for 
application in pharmaceutics, cosmetics, and other fields.  
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Tavano at al.76-78 developed a few types of niosomes and demonstrated that they could act 
as carrier for anticancer drugs doxorubicin (DOX) and 5-Fu, with good encapsulation, 
controlled release profile, and significant reduction in cancer cell viability. They also 
reported niosomes could be excellent carriers for antioxidants. When loaded in niosomes, 
resveratrol, alpha-tocopherol and curcumin lead to promoted ability to reduce free 
radicals.79 Marianecci at al.80 recently comprehensively reviewed niosomes concerning 
formations and applications in drug delivery and targeting since 80s of last century.  
A library of 36 lipodoids are examined for siRNA delivery from lipid-like materials, including 
six amines, three alkyl-acrylates, and three alkyl-acrylamides.81 Interestingly, when two 
ineffective single lipid-like materials are formulated into one delivery vehicle, the binary 
combination system can induce nearly complete knockdown of firefly luciferase and factor 
VII in HeLa cells and in mice, respectively.  
Chien et al.82 prepared ‘liposome’ from synthetic cationic cardiolipin analogue (CCLA) for 
siRNA delivery. The results show seven-fold higher transfection efficiency in mice than the 
commercially available 1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) 
(DOTAP)-based liposome, 62% of growth inhibition in cancer cells, and 73% of tumour 
growth suppression in SCID mice bearing human breast xenograft tumours. 
Monodisperse ‘liposomal’ particles made from di-alkylated amino acids based upon 
arginine DiLA2 compounds were prepared by Adami et al.83 with particle size of 100 nm. 
Their pH dependent phase transition to hexagonal phase facilitates efficient siRNA release 
from endosome to cytosol. They also noted the improved long term tolerability, ease of 
manufacture, potential for metabolism and high in vivo delivery efficiency of this system.  
2.3 Inorganic nanoparticles with low cytotoxicity 
Widely explored inorganic gene carriers include metals and metal oxides, silica-based 
NPs, carbon-based NPs, calcium phosphate NPs, and layered double hydroxide NPs.  
2.3.1 Metals and metal oxides 
Gold nanoparticles (Au NPs) are the most popular metal NPs applied in nanomedicine for 
centuries. Faraday84 firstly reported Au NPs in 1857, attributing the red colour to its 
colloidal nature, and a half century later, Mie85 rationalised the visible absorption of 
colloidal Au NPs, which depends on the adsorption and reflection of metal. Au NPs can be 
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synthesised in the lab with the size ranging from 1 to 150 nm and a variety of shapes like 
spheres, rods, shells, cages, prisms, triangles, tetrapods, dogbones and cubes. Au NPs 
can be stabilised by a wide range of ligands, surfactants, polymers, dendrimers and 
biomolecules, etc. The most robust Au NPs is stabilised by thiolates via the strong Au-S 
bond, which was firstly disclosed by Giersig and Mulvaney.86  
Hydrophobic drugs can be incorporated inside the ligand shell surrounding Au NPs by a 
non-covalent way to achieve controlled delivery. Kim et al.87 prepared Au NPs-payload 
conjugates (AuNPZwit-Bodipy, TAF, and LAP) by a solvent replacement method from Au 
NPs core (AuNPZwit) and three hydrophobic guest compounds: e.g. 4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene (Bodipy) as a fluorescent probe and the highly hydrophobic 
therapeutics tamoxifen (TAF) and lapachone (LAP) as drugs. They found this delivery 
system can stably entrap drugs in the hydrophobic pocket of Au NPs and efficiently deliver 
dyes/drugs into MCF-7 cells without uptake of carrier NPs by membrane-mediated 
diffusion. The drugs loading and cellular delivery are illustrated in Figure 2-14. 
 
Figure 2-14 Structure of Au NPs with loaded hydrophobic drugs and its cellular delivery 
through monolayer-membrane interactions, reproduced from Ref. 87 
By subsequent biomolecular substitution of a thiolate ligand, oligonucleotides, peptides 
and PEGs are easily attached to Au NPs. Rosi et al.88 conjugated antisense 
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oligodeoxyonucleotides (asODNs) to the Au NPs surface with thiol groups, and found the 
Au NPs-asODNs composites readily enter C166, HeLa, NIH-3T3, and MDCK cells (>99% 
uptake). They also found the bound asODNs remain undigested by DNAse after 48 h of 
incubation in the cellular environment, and the enhanced green fluorescent protein (EGFP) 
expression reduced. This has proved the protection of nucleic acids by Au NPs via 
condensing the gene materials (Figure 2-15). 
 
Figure 2-15 asODNs protected by Au NPs from enzyme degradation, reproduced from 
Ref. 88 
Oishi et al.89 developed a smart PEGylated Au NPs for siRNA delivery by complexing 
poly(ethylene glycol)-block-poly(2-(N,N-dimethylamino)ethyl methacrylate) copolymer 
(PEG–PAMA) and Au NPs, and then conjugating thiolated siRNA. The PEGylated Au NPs 
with thiolated siRNA achieve an effective RNAi activity with 65 % gene knockdown, which 
is similar to the commercial Oligofectamine (60 % inhibition).  
2.3.2 Silica-based nanoparticles 
Mesoporous silica nanoparticles (MSNs) were firstly introduced by Beck and coworkers in 
1992 and the first family of MSNs was named as M41s.90, 91 Later on, highly ordered MSNs 
and SBA-15 MSNs were also synthesised and intensively investigated. MSNs have drawn 
much attention in nanomedicine because of its large surface area, high pore volume, 
tunable pore structure as well as particle size, low mass density, good biocompatibility, 
and ease of surface functionalisation. In 2001, MSN material was firstly reported as a drug 
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delivery system.92 Recently, Yu’s group explored MSNs with rough surfaces (mimicking 
viruses), and found enhanced cellular delivery of curcumin to KHOS cells.93, 94  
To overcome the limitations of pure MSNs, magnetism and luminescence functionalised 
MSNs help for drug targeting and tracking, and various silica pore-blocking caps are used 
to develop MSN-based drug delivery system with external stimuli triggered release to 
prevent “zero-premature release”, including NPs, organic molecules, and supra-molecular 
assemblies. The stimuli-responsive strategies are also diverse, such as chemical, pH, 
electrostatic interaction, enzymatic, redox, temperature, and photo-irradiation. Yang et al.95 
extensively summarised the functionalised MSNs-based drug delivery systems and 
illustrated the major types, as shown in Figure 2-16. 
 
Figure 2-16 Functionalised MSNs-based sustained/controlled drug delivery systems, 
reproduced from Ref. 95 
Recently, Zhou et al.97 developed a DNA-gated multifunctional MSN-based delivery 
system, which is multi-responsive to disulphide reducing agents, elevated temperature, 
and DNase for co-delivery of genes and drugs with controlled release (Figure 2-17). Zhang 
et al.98 developed traceable and targeted MSN-based nanocarrier by capping MSN coated 
QDs with DNA hybrid, and the drug release can be triggered by overexpressed 
endogenous miR-21 in pathological cells which competitively hybridises with DNA. This 
also provides the possibility for co-delivering drugs and genes. Zhang et al.99 engineered a 
more complicated multifunctional MSN-based nanocarrier by incorporating polymer PEG 
on MSNs, functionalising with cyclodextrin by disulphide bond bridging for pH and 
glutathione triggered release, and folate ligand for targeting. Xiao et al.100 designed a dual-
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responsive MSN-based drug carrier by functionalising MSN surface with peptide ligand via 
disulphide bonds, with the peptide being then PEGylated and protected by methoxy PEG 
(MPEG) with benzoic-imine bond. The multi-functionalised NPs can be easily taken up by 
tumour cells because of the peptide targeting ligand, while the loaded drug is released by 
hydrolysis of benzoic-imine bond and cleavage of disulphide bond in tumour site.  
 
Figure 2-17 Schematic diagram of a co-delivery system based on MSNs to deliver Dox 
and Bcl-2 target siRNA simultaneously to A2780/AD human ovarian cancer cells, 
reproduced from Ref. 96 
Quite a few groups have also reported loading DNA/siRNA in PEI modified MSNs, 
providing protection to DNA/siRNA from enzyme degradation, and resulting in enhanced 
gene delivery.101-105 Simultaneous co-delivery of drug and nucleic acids has also been 
reported by researchers, and effective silencing activity and enhanced anticancer action 
(even in the multidrug resistant cancer cell) were found.96, 106, 107 Figure 2-17 shows the 
schematic diagram for MSNs as a co-delivery system for Dox and siRNA. Dendrimer-
capped mesoporous silica showed higher transfection efficiency than commercial 
transfection reagent PolyFect, SuperFect, and Metafectene.108 
2.3.3 Carbon-based nanoparticles 
It is widely accepted that carbon nanotubes (CNTs) were firstly discovered by Iijima in 
1991; however there were several earlier reports which introduced similar carbon 
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structures by Radushkevich and Lukyanovich in 1952, Bacon in 1960, and Oberlin et al. in 
1976.109-112 Two years later, Iijima and Ichihashi reported single shell CNTs in 1 nm 
diameter size.113 CNTs are long cylinders of covalently bonded carbon atoms, which have 
gained much interest as drug delivery vehicles, owing to the high surface area, enhanced 
cellular uptake and facile conjugation with much therapeutics. The basic structure of CNTs 
is shown in Figure 2-18. 
 
Figure 2-18 The basic structure of CNTs 
Wong et al.114 reviewed CNTs as a type of nanocarrier for small molecule drugs in 2013, 
including anticancer drugs: topoisomerase inhibitors, antimetabolites, antimicrotubules, 
and non-anticancer drugs: antimicrobials, anti-inflammatories, antihypertensives, 
antioxidants, etc. CNTs as vectors for gene delivery were reviewed by Bates and 
Kostarelos115 in 2013, including single-walled nanotubes (SWNTs) and multi-walled 
nanotubes (MWNTs), concerning the delivery of plasmid DNA, siRNA and mRNA, ODN 
and aptamer DNA/RNA.  
Wang et al.116 prepared PEI functionalised SWNTs to deliver siRNA to PC-3 cells, and 
found severe apoptosis and strong suppression in vitro. After conjugated with a tumour 
target peptide NGR, they also found significant tumour cell growth inhibition. Wu and co-
workers117 grafted MWNTs with PEI and further conjugated to prostate stem cell antigen 
monoclonal antibody (mAb) (Figure 2-19), and found the resultant NPs can specifically 
target the cancer cells and suppress tumour growth with great potential as a targeted 
ultrasound contrast agent.  
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Figure 2-19 Schematic diagram of synthesis process for CNT-PEI-mAb, reproduced from 
Ref. 117 
 
Figure 2-20 Schematic illustration of functionalised SWNTs for loading siRNA, reproduced 
from Ref. 118  
Anderson et al.118 functionalised SWNTs with mPEG-DSPE, then coated with cationic 
polymer PAH, and loaded siRNA via electrostatic interactions (Figure 2-20). Successful 
internalisation of the SWNT/siRNA nanoplexes by pancreatic cancer cells was observed, 
resulting in down regulation of the target gene, and the functionalised SWNTs are proved 
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to be highly biocompatible. Dendrimer modified CNTs are also found having higher gene 
transfection efficiency.119 
2.3.4 Calcium phosphate 
Calcium phosphate (CaP) is a family of minerals containing calcium ions (Ca2+) and 
orthophosphates (PO43-), metaphosphates or pyrophosphates (P2O74-), occasionally with 
hydrogen or hydroxide ions, which includes monocalcium phosphate Ca(H2PO4)2, 
dicalcium phosphate CaHPO4, tricalcium phosphate Ca3(PO4)2 (sometimes referred to 
simply as calcium phosphate or calcium orthophosphate), hydroxyapatite Ca5(PO4)3(OH), 
apatite Ca10(PO4)6(OH, F, Cl, Br)2, and octacalcium phosphate Ca8H2(PO4)6.5H2O.  
CaP has been used for gene delivery because of its safety, good biocompatibility, and a 
relatively facile and cost-effective preparation. Conventional CaP-DNA/siRNA composite 
particles can be obtained typically by a microemulsion method, mixing a phosphate ion 
emulsion and a calcium ion emulsion supplemented with DNA/siRNA under neutral pH in a 
controlled Ca/P ratio. DNA/siRNA is compacted and protected by CaP in these composites 
and the composites can be easily taken up by cells. Furthermore, the composites can 
successfully escape from the endosomes by the ‘proton sponge’ effect, where CaP is 
easily dissolved in an acidic environment, causing high osmotic pressure in endosomal 
vesicles and influx of much water, and then rupture of endosomal vesicles.  
In general, the critical disadvantages of CaP-based gene delivery system are their 
insufficient transfection efficiency and poor reproducibility compared with other nonviral 
systems. Recently, Huang’s group proposed a new CaP-based gene delivery system by 
coating lipids around the CaP particles,70, 71, 120 where lipids interact with Ca ions 
covalently to form stable inner lipid coating. Later, by traditional thin lipid film hydration 
method, the outer layer of lipid is formed around the CaP-lipid particles. Since the inner 
and outer layer of lipids are coated in separate steps, the stability and charge property of 
CaP-lipid particles can be controlled by choosing neutral or negatively/positively charged 
lipids. Moreover, PEGylated lipids can also be incorporated in this system to further 
improve the circulation lifetime of this composite system. The CaP-lipid composites have 
proved to induce ~ 40 fold higher siRNA delivery than the lipid based formulation. The 
preparation of CaP-siRNA-lipid particles and the interaction between calcium ions and lipid 
head groups are illustrated in Figure 2-21.  
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Figure 2-21 Schematic diagram for preparing CaP-lipid composites for siRNA delivery from 
microemulsion method and the interaction between calcium ions and lipid head groups 
which facilitates CaP-lipid particles formation, reproduced from Ref. 71 
2.3.5 Layered double hydroxides 
Layered double hydroxides (LDHs), also known as anionic clays or hydrotalcite-like 
compounds (HTlcs), are a family of inorganic layered materials, which can be found 
naturally as minerals or can be easily synthesised in the lab with controlled compositions. 
LDH composition can be expressed in a general formula [M2+1-x M3+x(OH)2] (An-x/n·mH2O), 
where M2+ can be most divalent ions, such as Mg2+, Ca2+, Cu2+, Zn2+, Co2+, Ni2+, Fe2+; M3+ 
can be most trivalent ions, such as Al3+, Fe3+, Cr3+; x=0.2-0.33, which means the M2+/M3+ 
molar ratio is 2.0-4.0; x also means the positive charge density of LDH; Am- represents any 
type of anions, and the common ones are CO32-, Cl-, NO3-, OH-, SO42-, CrO42-; m=1-3x/2.  
The schematic 3-D structure of LDH is shown in Figure 2-22. In every single layer, every 
divalent metal cation is located in the center of the octahedron constructed by six hydroxyl 
groups. These octahedra are connected one another by edge-sharing, forming the two-
dimensionally infinite sheet (or layer), which is similar to the basic structure of brucite 
Mg(OH)2. Partial substitution of divalent ions in the brucite-like hydroxide layer by trivalent 
ions leads to the positive charge sheets, which is balanced by the negative charged anions 
intercalated in the interlayer. Then the brucite-like layers can stack upon one another via 
electrostatic interactions between the layers, forming the three dimensional structure. 
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Figure 2-22 Schematic 3-D structure of LDH, reproduced from Ref. 121 
2.3.5.1 Pure LDH NPs for drug/gene delivery 
The partial substitution of magnesium ions in the brucite-like hydroxide layer by aluminium 
ions leads to the positive-charged property of the hydroxide sheets. This enables 
incorporation and protection of negatively charged biomolecules, such as CMP (cytidine-
5´-monophosphate), AMP (adenosine-5´-monophosphate) and GMP (guanosine-5´-
monophosphate), ATP (adenosine triphosphate), amino acids, peptides, DNA, and siRNA 
onto LDH via electrostatic interactions. The exchangeable interlayer can also 
accommodate negatively charged anions and small molecule drugs by ion-exchange or 
one-step synthesis (e.g. coprecipitation). The LDH-biomolecules hybrids gain extra 
stabilisation energy due to electrostatic interactions between cationic hydroxide layers and 
anionic biomolecules. The charge neutralisation facilitates the penetration of LDH-nucleic 
acid hybrids into cells through endocytosis, since this hybrid greatly reduces the 
electrostatic repulsive interactions between negatively charged cell membranes and naked 
anionic biomolecules.  
Recently, Rives et al.122 reviewed LDH for drug delivery and its controlled release. A large 
variety of drugs are included in this review, such as antibiotics, anticancer agents, 
vitamins, amino acids and peptides, anticardiovascular agents, diabetes treatment drugs, 
antifibrinolytic agents, antihypertensives, antimycotic agents, anticoagulants, osteoporosis, 
antioxidants, and immunosuppressant corticosteroids.  
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Gu and co-workers used LDH as a carrier for anti-restenotic pharmaceutical reagent low 
molecular weight heparin (LMWH), finding a sustained release of LMWH from LDH-LMWH 
hybrids in the physiological condition, enhanced cellular uptake of LMWH-LDH hybrids by 
smooth muscle cells (SMCs), improved ability of LMWH to inhibit SMC proliferation and 
migration. This shows LDH a promising delivery system for anti-restenotic drug LMWH.123-
125 Figure 2-23 shows the schematic structure of LDH-LMWH.  
 
Figure 2-23 Schematic illustration of LMWH intercalated in MgAl-Cl-LDH, reproduced from 
Ref. 123 
In 1999, Choy’s group firstly reported the biomolecule-LDH hybrids, including AMP-LDH, 
CMP-LDH, GMP-LDH, and DNA-LDH. The biomolecules are protected and stabilised by 
LDH, and moreover they can be recovered in acid conditions without loss of chemical and 
biological integrity.126 This work pioneered the research for using LDH as the gene 
material reservoir. In the following few years, the cellular uptake behaviour of LDH-
biomolecule and cytotoxicity of LDH were studied by the same research group and the 
results show LDH can be a good gene delivery vector.127-129 
In 2004, Tyner et al.130 delivered a full gene encoding green fluorescent protein to a variety 
of cell types, e.g. 9L glioma cells, JEG3 choriocarcinoma placental cells, and cardiac 
myocytes, and found all cells can internalise and tolerate the LDH-DNA nanocomposites, 
express the gene with 70 % to 90% transfection efficiency after 48 h of incubation. In 
2009, Masarudin et al.131 transfected the same gene into African monkey kidney (Vero3) 
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cells using MgAl-LDH as a nanocarrier. They found LDH can provide protection to the 
plasmid DNA from degradation and the transfected cells exhibit fluorescence 12 h post 
treatment. In our research group, Ladewig et al.132, 133 associated plasmid DNA with LDH 
nanoparticles and achieved successful transfection in adherent cell lines HEK 293T, NIH 
3T3, COS-7 and CHO-K1, although the aggregation between LDH and plasmid DNA were 
observed. In 2011, Li et al.134 found LDH-plasmid DNA complex has high transfection 
efficiency in vivo and the complex enhances the in vivo anti-melanoma immune response 
significantly. These indicate further that LDH can be a promising vector for gene delivery.  
In recent years, using LDH NPs as vector for siRNA has been explored by researchers. 
Our research group attempted to use LDH NPs for delivering siRNA to mammalian cells, 
which induced 99% of cellular uptake (even better than commercial transfection agent 
Lipofectamine®). Furthermore, marked down-regulation of protein expression in HEK 293T 
cells and primary cultured neurons was also observed, which demonstrates LDH NPs can 
be adopted as an efficient delivery vehicle for siRNA.132, 135-139 Co-delivery of anticancer 
drug and siRNA by LDH has also been explored by our group. By loading anticancer drug 
5-fluorouracil (5-Fu) and cell death siRNA (CD-siRNA) simultaneously on LDH NPs, 
significantly enhanced cytotoxicity to cancer cells MCF-7, U2OS and HCT-116 was 
observed.140 This provides a better cancer treatment solution than chemotherapy or gene 
therapy only. 
Remarkably, MgAl-LDH shows no discernible cytotoxic effect because of its 
physicochemical nature.124, 137, 139, 141 The hydroxide layer will be dissolved gradually in the 
weakly acidic condition, such as in endosome or lysosome. This dissolution releases the 
loaded gene/drug, but simultaneously gives some magnesium and aluminium ions that are 
physiologically-friendly and can be excreted through ion tunnels. For example, the escape 
of LDH-drug/siRNA hybrid from endosome is via “increasing endosomal osmotic 
pressure”. After LDH-drug/siRNA is taken up via endocytosis, H+ influxes into endosome 
partially dissolves the hydroxide layer of LDH, which results in a higher concentration of 
Mg2+ and Al3+, and then a higher osmotic pressure in endosome. The higher osmotic 
pressure thus causes more water influx in endosome, which finally causes the rupture of 
endosome, releasing LDH-drug/siRNA or drug/siRNA into cytoplasma.136, 142 The proposed 
cellular uptake and payload release mechanisms are shown in Figure 2-24. 
Thus, LDH nanoparticles possess many advantages as an excellent gene delivery system. 
However, the LDH-gene complexes form aggregates in the blood flow, which possibly clot 
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the blood flow and cause animal to die. This is a big barrier for LDH nanoparticles to be an 
efficient in vivo vector. LDH-based hydridisation systems have been developed by 
researchers for enhanced therapeutic efficacy, hindering LDH NPs forming aggregation, 
and widening the spectrum of payloads.  
 
Figure 2-24 Proposed cellular uptake and payload release mechanism of LDH, (a) Drug-
LDH nanohybrids approach cell membrane, (b) drug-LDH nanohybrids are internalised via 
clathrin-mediated endocytosis, (c) nanohybrids are transported inside the cell through 
early endosome, (d) in late endosome, LDHs are partially dissolved due to the slight 
acidity, (e) in lysosome, drugs are released, (f) LDHs are externalized via exocytosis, 
reproduced from Ref. 143 
2.3.5.2 LDH hybridised with inorganic vector(s) 
Wang and co-workers144 developed a Gd-doped Mg-Al-LDH/Au nanocomposite, which has 
high loading capacity for non-anionic anticancer drug DOX with pH-responsive DOX 
release profile in PBS at varied pH conditions. The composite also efficiently transports 
DOX into HeLa cells; releases DOX in the acidic cytoplasm and then causes cell death. 
On the other hand, this nanocomposite shows superior performance for CT-MR imaging 
both in vitro and in vivo than the commercial MRI and CT contrast agents. Moreover, the 
composite shows negligible cytotoxicity and no detectable tissue damage.  
Zhang et al.145 prepared core-shell structure of magnetic nanohybrids by coating MgAl-
LDH on magnesium ferrite magnetic cores with intercalated ibuprofen by one-step co-
precipitation method. In the absence of external magnetic field, the drug release from the 
magnetic nanohybrids can be tuned by the magnetic core content in the nanohybrids, 
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while under external magnetic field in consecutive “ON-OFF” mode, magnetically 
controlled pulsatile release profile was observed. They proposed this magnetic LDH hybrid 
could be a promising drug targeting and magnetically tunable delivery system. 
 
Figure 2-25 Illustration of core@shell LDH@SiO2 NP synthesis and structure, reproduced 
from Ref. 146  
 
Figure 2-26 Schematic diagram for preparing LDH-MSN nanorattles with LDH core and 
MSN shell, reproduced from Ref. 147 
Bao et al.146 synthesised core@shell structure of LDH@SiO2 and used it for loading 
ibuprofen. The nanocomposite shows slower release of ibuprofen in PBS compared to 
MSN, which is only due to the LDH core. The synthesis procedure and LDH@SiO2 
structure is shown in Figure 2-25. In the same year, Liu et al.147 synthesised an LDH-MSN 
hybrid system by coating silica on LDH surface, forming LDH-MSN nanorattles, and they 
used the hybrid system for delivering model fluorophore FITC. Aside from pH triggered 
release of payload, the LDH-MSN hybrids possess several advantages over conventional 
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carriers, such as high loading amounts, high surface area, ease of functionalisation and 
controllable particle size and void size, interstitial space between core and shell that can 
be used for encapsulation of molecules or NPs. Figure 2-26 shows the schematic 
procedure for preparing LDH-MSN nanorattles with LDH core and MSN shell.  
Zheng et al.148 also developed LDH-MSN hybrid system encapsulating the guest 
molecules Ru(bpy)3Cl2, where LDH nanosheets are adsorbed on the surface of MSNs by 
electrostatic interaction. This hybrid system combines the pH-responsive payload release 
property of LDH and advantage of MSNs for encapsulating molecules inside nanopores, 
while it avoids the tedious surface modification of MSNs for pH-triggered release of guest 
molecules, hinders LDH NPs forming aggregation, and widens the spectrum of payloads. 
Figure 2-27 shows the procedures for synthesising LDH nanosheets capped MSNs as a 
pH-responsive release system. 
 
Figure 2-27 Schematic diagram for preparing LDH-MSNs hybrids, reproduced from Ref. 
148 
Core-shell LDH-MSN hybrid is also used as an adjuvant for DNA vaccine, where much 
higher transfection efficiency and expression of IFN-γ, IL-6, CD86, and MHC II were 
observed than LDH and SiO2 only.149  
2.3.5.3 LDH hybridised with polymer(s) 
Ribeiro and co-workers150 developed a new pectin-coated chitosan-LDH nanocomposite 
for delivering the most used non-steroid-anti-inflammatory drug (NSAID, also known as 5-
aminosalicylic acid, 5ASA). This composite profits from the mucoadhesiveness of 
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chitosan, while pectin provides protective coating for chitosan and LDH to keep the system 
resistant to pH changes (low pH in the stomach when oral administration is used), and 
LDH host offers opportunity for controlled drug release. Figure 2-28 shows the proposed 
structure of pectin coated chitosan-LDH nanocomposite loaded with drug 5ASA.  
 
Figure 2-28 Schematic structure of pectin coated chitosan-LDH nanocomposite loaded 
drug 5ASA, reproduced from Ref. 150 
Mahkam and coworkers151 combined pH-sensitive drug host Zn-Al-LDH and pH-sensitive 
polymer alginate (a polysaccharide widely used for drug encapsulation) to form a new 
hybrid material. Acting as crosslinker in the hybrid, LDH restricts the mobility of pH-
sensitive polysaccharide chains, and then slows down their swelling and dissolution rates. 
The LDH-alginate hybrid shows sustained drug release either in the presence or absence 
of glucose phosphate. 
Hu et al.152 grafted LDH surfaces by 2-(dimethylamino)-ethyl methacrylate (DMAEMA) 
using surface-initiated atom transfer radical polymerization (ATRP) technique. A series of 
well-defined cationic LDH-PDs consisting of LDH and disulphide-linked cationic 
P(DMAEMA) brushes with different lengths were obtained with better ability to condense 
plasmid DNA, enhanced cellular uptake, and higher gene delivery to COS7 and HepG2 
cells. Figure 2-29 shows the schematic diagram illustrating the process for grafting 
P(DMAEMA) on LDH surfaces.  
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Ciobanu et al.153 successfully intercalated carboxymethyl-β-cyclodextrins (CMCDs) into 
interlayers of LDH via reconstruction method. The resultant hybrid could encapsulate 
various organic guests, and prolong their release time compared to LDH host only. This is 
because the organic guests can be included in the cavity of CMCDs. Figure 2-30 shows 
the schematic illustration for intercalating CMCDs into LDH interlayers and following 
organic guest encapsulation.  
 
Figure 2-29 Schematic illustration of P(DMAEMA)-grafted LDH hybrid preparation process, 
reproduced from Ref. 152 
San Román et al.154 prepared LDH-drug-PLA nanocomposite by dispersing LDH-drug in 
semicrystalline PLA, formed a composite with LDH-drug supported on PLA. Much slower 
drug release from the nanocomposite than from LDH only was observed which related to 
the base-catalysed decomposition of PLA. 
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Figure 2-30 Schematic diagram illustrating intercalation of CMCDs into LDH and 
encapsulating organic guests, reproduced from Ref. 153 
Xia et al.155 modified LDH NPs with PEG and FA for disguise function and targeting, using 
(3-aminopropyl) trimethoxy silane (APTMS) as linker agent. The modified particles show 
good dispersibility due to the space steric effect of the modified layers, so they could be 
used in drug delivery. 
Alcântara et al.156 prepared a nanocomposite beads from LDH (with drug ibuprofen 
intercalated in the interlayers), a polysaccharide alginate, and a highly hydrophobic protein 
zein. The resultant composites show a more sustained release of drug than only loaded in 
LDH because it requires the diffusion of water inside the matrix to LDH, while the 
hydrophobicity of protein lowered the water uptake of the composites. Figure 2-31 shows 
the schematic diagram of LDH-alginate-zein nanocomposites loaded with ibuprofen.   
 
Figure 2-31 Schematic illustation of LDH-alginate-zein nanocomposites loaded with drug 
ibuprofen for more sustained release, reproduced from Ref. 156 
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2.3.5.4 LDH hybridised with lipid(s) or lipid-like surfactant(s) 
Tyner et al.157 incorporated poorly water soluble drug camptothecin (CPT) in micelles 
derived from negatively charged surfactant, and then encapsulated micelles into the 
interlayer of LDH by ion exchange process. This method increases three-fold solubility of 
CPT. Figure 2-32 shows the schematic diagram for LDH-micelle formation.  
 
Figure 2-32 Schematic illustration of LDH-micelle hybrid formation, reproduced from Ref. 
157 
Bégu et al.158 reported a hybrid system for sustained lipophilic drug delivery prepared from 
self-assembled unilamellar anionic liposome intercalated in interlayer of LDH. This also 
provides a possibility to deliver non-ionic water soluble drugs by LDH.  
Hou’s group159-161 developed a class of hybrid systems by inducing surfactant derived 
liposome formation using LDH. They confirmed the liposomal vesicle formation with 
entrapped LDH particles by TEM and they believed this system is a promising vector for 
drug delivery. 
Huang and co-workers162, 163 prepared a dextran-magnetic layered double hydroxide-
fluorouracil liposome (DMFL) system by reverse evaporation method. They found 
hexagonal skeleton of dextran-magnetic layered double hydroxide-fluorouracil (DMF) can 
be encapsulated by lipid bilayer on TEM images, and the encapsulation efficiency of 
fluorouracil (FU) is determined to be ~ 85%. The average diameter size of DMFL is ~ 160 
nm, and the release of FU from DMFL in PBS shows a sustained profile. Moreover, DMFL 
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shows higher cytotoxicity to human ovarian adenocarcinoma cancer cells (SKOV3) than 
other FU formulations at the same concentrations and intervention time. 
 
Figure 2-33 Negative stained TEM image of Mg3Al-LDH-SDS/DTAB composites (A) and 
schematic illustration for the vesicle formation mechanism (B), reproduced from Ref. 160 
2.4 Summary 
A broad range of non-viral vectors have been developed for improving the therapeutic 
efficiency of gene therapy, including polymers, liposomes, and cell penetrating peptides 
(CPPs), inorganic metal and metal oxide nanoparticles (NPs), carbon nanotubes (CNTs), 
mesoporous silica nanoparticles (MSNs), calcium phosphate (CaP) NPs and layered 
double hydroxide (LDH) NPs. However, each pure delivery system has been noted to have 
its drawback(s).  
Some hybridisation systems have shown promising in efficient drug/gene delivery by 
merging the advantages of two or more worlds, while overcoming their limitations. Thus 
this PhD project aims to develop a composite system from most biocompatible organic 
delivery vehicles liposomes and highly efficient, friendly inorganic LDH NPs. The resulted 
composite system is expected to combine the advantages from LDH NPs for high gene 
loading capacity, efficient transfection and endosomal escape, and from liposomes for 
good colloidal stability, while avoid the downsides of LDH for aggregation in blood 
circulation and liposomes for inefficient endosomal escape and payload release. 
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Chapter 3 Materials and Methods 
3.1 Materials 
Normal chemicals were used as bought from suppliers, including (sorted alphabetically): 
chloroform (CHCl3, Merck); aluminium chloride hexahydrate (AlCl3·6H2O, Fluka, ≥99.0%); 
aluminium nitrate nonahydrate (Al(NO3)3·9H2O, Fluka, ≥98.0%); DMSO (Sigma-Aldrich, 
BioReagent, ≥99.9%); DOPA (1,2-dioleoyl-sn-glycero-3-phosphate(sodium salt), Avanti 
polar lipids); egg PC (L-α-phosphatidylcholine (Egg, Chicken), Avanti polar lipids); FITC 
(fluorescein isothiocyanate isomer I, Sigma-Aldrich); magnesium chloride hexahydrate 
(MgCl2·6H2O, Sigma-Aldrich, 99.0-102.0%); magnesium nitrate hexahydrate 
(Mg(NO3)2·6H2O, Fluka, ≥99.0%); methanol (Fluka, ≥99.0%); nitric acid (ACS reagent, 
70%, Sigma-Aldrich); sodium hydroxide (NaOH, Fluka, ≥97.0%, pellets); tert-butanol 
(tertiary butyl alcohol, TBA, Sigma-Aldrich); Triton™ X-100 (Sigma-Aldrich).  
Biological reagents used in this thesis include (sorted alphabetically): 25 bp dsDNA ladder 
(Invitrogen™); agarose powder (molecular grade, Bioline); DMEM (Dulbecco's Modified 
Eagle Medium, L-glutamine, Gibco®); DNA-Cy3 (PAGE purity, Sigma-Aldrich); DPBS 
(Dulbecco's phosphate-buffered saline, Gibco®); dsDNA DCC1 (sequencing/PCR purity, 
geneworks); FBS (Fetal Bovine Serum, Gibco®); gel loading dye (Invitrogen™); gel-Red 
(Invitrogen™); MTT reagent (5 mg/mL in PBS buffer, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, Molecular Probes®); Oligofectamine™ (Life Technologies); 
trypsin-0.25%EDTA (Gibco®); UltraPure™ TBE Buffer (Invitrogen™). FBS was treated in 
56 °C water bath for 30 min before use for heat inactivation.  
3.2 Preparation of various nanoparticles (NPs) 
3.2.1 LDH and LDH-FITC NPs  
sLDH NPs were prepared by non-aqueous precipitation, followed by heat-treatment, 
purification and dispersion in water (Figure 3-1), which was modified from Pinnavaia’s 
method.1 Typically, 10 mL methanol solution containing 6 mmol of Mg(NO3)2·6H2O and 2 
mmol of Al(NO3)3·9H2O was added drop-wise to a 40 mL of methanol solution containing 
16 mmol NaOH under vigorous stirring. The mixture was stirred for 30-40 min, the 
precipitate slurry was then collected through centrifugation, redispersed in 40 mL fresh 
methanol and transferred to a Teflon®-lined autoclave, followed by heat-treatment at 100 
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°C for 18 h. After cooling the sample to room temperature, the precipitate slurry was 
collected through centrifugation, and washed twice with deionised water (DI water). The 
final collected slurry was manually dispersed in 40 mL of DI water, followed by standing at 
room temperature with occasional hand-shaking. This dispersion became transparent, 
resulting in a homogeneous LDH suspension after 4-6 days with the LDH mass 
concentration determined to be 6 to 7 mg/mL (∼50% yield), Z-average diameter size ~ 40 
nm.  
 
Figure 3-1 Schematic diagram for sLDH synthesis 
Large LDH (L-LDH) particles were synthesised by vigorously mixing 10 mL of aqueous 
solution containing 3.0 mmol of MgCl2·6H2O and 1.0 mmol of AlCl3·6H2O with 40 mL of 
0.15 M NaOH solution for 10 min at room temperature.2-4 The LDH slurry was collected by 
centrifugation and then washed twice with DI water (40 mL), and resuspended in DI water 
(40 mL), after which the suspension was transferred to a Teflon®-lined autoclave and 
hydrothermally treated at 100 °C for 16 h. The suspension contained approximately 4 
mg/mL of homogeneously dispersed Mg2Al-LDH nanoparticles, with a Z-average diameter 
particle size ~ 100 nm.  
Both small and large LDH-FITC NPs were prepared by ion-exchange method. FITC-Na 
solution (0.05 mmol) was mixed with 1 mmol of LDH slurry and then shaken on a 
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reciprocal shaker for 1 h. After ion-exchange, the unchanged FITC and residual 
NaNO3/NaCl were separated and washed. Small and large LDH-FITC NPs were 
redispersed in DI water, and then followed by hydrothermal treatment.  
3.2.2 LDH-liposome composites  
LDH-liposome composites were prepared by two different methods, hydration of thin lipid 
film (HTLF) method and hydration of freeze dried matrix (HFDM) method.5-8  
HTLF method: Egg PC (20-100 mg) was dissolved in chloroform (~ 5mL) and dried in a 
round bottom flask (RBF, 25-100 mL size) on a vacuum rotary evaporation system, then 
the thin lipid film was hydrated with sLDH suspension (2-10 mL, 6-24 mg/mL). Un-
associated sLDH NPs were separated by centrifugation washing.  
HFDM method: LDH suspension mixed with sucrose solution at volume ratio of 1:1, and 
then mixed with EPC in TBA (tert-butanol / tertiary butyl alcohol) solution at volume ratio of 
7:3. LDH:DNA mass ratio = 20:1, lipid:DNA mass ratio = 20:1, and sucrose:lipid mass ratio 
= 190 :1 were used in the formulations. A clear solution should be obtained and then snap-
frozen in dry ice. This frozen mixture was dried on a freeze-dryer overnight and then 
hydrated with DI water. A typical process for sLDH-liposome formulation loaded with 
dsDNA is shown in Figure 3-2 with detailed reagent concentrations and volumes used. 
 
Figure 3-2 A typical process for sLDH-liposome formulation loaded with dsDNA 
3.2.3 Nucleic acid complexes 
Nucleic acids loaded in LDH NPs were realised by mixing LDH suspension with nucleic 
acid solution at mass ratio of 2:1, 5:1, 10:1, 20:1, and 40:1.  
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Nucleic acid loaded in LDH-liposome systems were conducted by three different ways. 
One way is to form LDH-nucleic acid associates first, then prepare the LDH-nucleic acid-
liposome composite (Figure 3-3A). Another way is to add the nucleic acid in 
lipid/water/TBA three phase mixture before snap freezing (Figure 3-3B). The other is to 
prepare sLDH-liposome composite first, then mix DNA solution with pre-formed LDH-
liposome composite suspension (Figure 3-3C). The resultant composites were denoted as 
LDH-DNA-Liposome, LDH-Liposome-DNA, and LDH-Liposome+DNA, respectively. The 
detail procedures for preparing the mixture before freeze-drying process are shown in 
Figure 3-3. 
  
Figure 3-3 Illustrated procedures for loading DNA in LDH-liposome composites by 
hydration of freeze-dried matrix (HFDM) method 
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3.3 Characterisations 
3.3.1 Dynamic light scattering (DLS) 
Particle sizes of LDH NP suspension, LDH-FITC NP suspension, LDH-nucleic acid 
associates and LDH-liposome composites, LDH-nucleic acid-liposome were measured by 
dynamic light scattering (DLS, also called photon correlation spectroscopy, PCS) 
technique on a zetasizer (Zetasizer Nano ZS, Malvern Instruments).  
3.3.2 X-ray diffraction (XRD) 
LDH suspension was deposited and dried on glass slides for XRD characterisation. 
Powder LDH was characterised by XRD as a pellet form. A Rigaku Miniflex X-ray 
diffractometer with Co Kα source (λ = 0.1789 nm) was used in this thesis. The samples 
were scanned from 2 θ = 2 ° to 60 ° (for suspension) and 80 ° (for powder) with step of 
0.02 ° and scanning speed of 2 θ = 2 °/min.  
3.3.3 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectra of LDH NPs were collected on a FTIR instrument (Nicolet 6700, Thermo 
Electron Corporation) with smart orbit unit. The samples were scanned 200 times from 
4000 cm−1 to 400 cm−1 at resolution of 1 cm−1.  
3.3.4 (cryo-)Transmission electron microscopy (TEM) 
LDH NPs were imaged by a TEM machine (JEOL 1011). Liposomes and LDH-liposome 
composites from hydration of thin lipid film (HTLF) method were imaged by a cryo-TEM 
facility (FEI, TECNAI F30) in the Centre for Microscopy and Microanalysis (CMM), The 
University of Queensland.  
3.3.5 Elemental analysis (EA) 
The carbon, hydrogen and nitrogen contents in powder LDH were characterised by an 
elemental analyser (FLASH EA 1112 series, Thermo Electron Corporation). Each sample 
was tested in triplicate. 
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3.3.6 Inductively coupled plasma-atomic emission spectrometry (ICP-
AES) 
The magnesium and aluminium contents in LDH NPs and LDH-liposome composites were 
tested by inductively coupled plasma-atomic emission spectrometry (ICP-AES, Varian 
VISTA AX Pro) after the LDH NPs or the LDH-liposome NPs were digested by nitric acid 
with heating at 80 °C.  
3.3.7 Ultraviolet–visible spectroscopy (UV-vis) 
Concentration of FITC was characterised by measuring absorbance on a UV-vis 
(Ultraviolet–visible spectroscopy) instrument (UV2450, SHIMADZU). Calibration curve was 
conducted by a series of known concentration of FITC sodium salt solution (0.5 ppm to 
10.0 ppm).  
3.4 Biological techniques 
3.4.1 Agarose gel electrophoresis 
A 2.5 % agarose gel with Gel-Red stain was made and then nuclei acids with/out LDH or 
LDH-liposome for binding were loaded in the wells (260 ng DNA was used in each well). 
Gel was imaged by a Bio-Rad imaging system after run at 90 V for 45 min in TBE buffer.  
3.4.2 Cell culture 
Human colon cancer HCT-116 cells were cultured in DMEM complemented with 10% v/v 
of FBS. The cells were subcultured at the split ratio of 1/4 to 1/8 at confluency 70 ~ 80% 
and the cell culture medium was changed every other day.  
3.4.3 Cell viability 
Human colon cancer HCT-116 cells were seeded in 96-well plates at a density of 2,000 
cells per well in 200 µL of cell culture media. After 24 h of incubation, cell culture media 
was replaced by 200 µL of fresh media with desired concentration of LDH or LDH-
liposome NPs. After 48, and 72 h further incubation, 20 µL of MTT reagent (5 mg/mL in 
PBS buffer) was added, followed by 2-4 h of incubation (dependent on cell density). Next, 
the cell culture media was discarded and 50 µL of DMSO was added to each well, followed 
by 10 min of incubation. Absorbance was read using a plate reader (Bio-Tek, USA) at 540 
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nm after 1 min of orbital shaking. A negative control group (only cell culture media, without 
cells) was used as background. A group without adding NPs was used as control. The cell 
viability was normalised to control. The experiments were conducted for at least two 
batches in triplicate. Data are presented as mean ± SEM (standard error of the mean). 
Two-way ANOVA was used to assess the statistical significance (commercial transfection 
reagent Oligofectamine™ (life technologies) as control group).  
3.4.4 Cellular uptake 
Cells were seeded in 6-well plates at density of 1*105 cells per well in 2 mL complete cell 
culture media. After 24 h of incubation, cell culture media was replaced by 1 mL of fresh 
media with/out desired concentration of NPs-DNA-Cy3 or LDH-FITC. Another 4 h (0.25 to 
8 h used for time-course investigation) of incubation later, cells were detached by trypsin-
EDTA from the plates after washed twice by PBS buffer, collected in 2 mL tubes, and 
washed twice again by PBS buffer, then finally fixed in certain volume of 2% PFA 
(paraformaldehyde). All treatments were done for at least two batches in triplicate. 
3.4.5 Flow cytometry 
A BD Accuri™ C6 Flow Cytometer System was used in this thesis and 10,000 cells were 
counted. Band pass filter 530/30 was used for detecting FITC, and 585/40 for Cy3. 
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Chapter 4 Synthesis and Characterisation of small 
Layered Double Hydroxide Nanoparticles 
 
Declaration for Chapter 4 
• Most parts of this chapter is published on Applied Clay Science 2014; 100, 66-75; 
doi: 10.1016/j.clay.2014.04.028 
• Thus this chapter is mainly based on the manuscript, with the supplementary tables, 
figures, and data being inserted into the proper sections. To keep consistency, the 
AmE spelling in the manuscript has been changed to BrE in this thesis; the format 
for unit has been changed from mg·mL-1 to mg/mL, etc. 
 
Abstract 
Small MgAl-layered double hydroxide (sLDH) nanoparticles (NPs) were prepared by a 
non-aqueous method with the Z-average diameter of ~ 40 nm. This method first requires 
co-precipitation of magnesium and aluminium nitrate solution with sodium hydroxide in 
methanol, followed by LDH slurry collection and re-suspension in methanol. The methanol 
suspension is then heated in an autoclave, followed by separation via centrifugation and 
thorough washing with deionised water (DI water). The NPs are finally dispersed in DI 
water into homogeneous aqueous suspension after 4-6 day standing at room temperature. 
In general, sLDH NPs have the Z-average size of 35-50 nm, the number-average size of 
14-30 nm and the polydispersity index (PdI) of 0.19-0.25. The prepared sLDH suspension 
is stable for at least 1 month when stored at fridge (2-8 °C) or ambient (22-25 °C) 
temperature. 
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4.1 Introduction 
In recent years, layered double hydroxide nanoparticles (LDH NPs) have demonstrated 
good therapeutic-carrier properties as well as highly efficient delivery vehicles for anionic 
drugs and nucleic acids, due to their favourable physical properties and low cytotoxicity.1-3 
LDHs, also known as anionic clays or hydrotalcite-like compounds (HTlcs), are a broad 
family of layered inorganic materials, whose composition can be expressed using the 
general formula [M2+1-xM3+x(OH)2](Am-x/n)·yH2O, where M2+ can be typical divalent ions and 
M3+ typical trivalent ions; x represents hydrated anions in the interlayer and can be of any 
types of anions, such as various inorganic and (bio)organic anions.4 The lamellar 
architecture alongside a well-distributed, condensed array of positive charges renders LDH 
an excellent carrier for a wide range of negatively charged therapeutics.5-8 Moreover, once 
the therapeutics are intercalated between LDH interlayers, they are physically protected 
from degradation. For example, LDH has been used as a DNA vector where intercalation 
has inferred protection of the gene from DNase-mediated degradation.9-12  
Given that negatively charged therapeutics do not readily transcend cellular membranes 
(which are also negatively charged), attempts to overcome this barrier can be effectively 
addressed by incorporating these anionic therapeutics within the interlayers of LDH, 
leading to efficient cellular uptake in vitro.3, 13 The high cellular delivery efficiency is also 
benefited from the innate ability of LDH to actively escape from endosomes (considered a 
major barrier to effective gene/drug delivery) through LDH-mediated endosomal buffering, 
which ultimately leads to counter ions and water ingress, rupture of endosomal vesicles, 
and release of intact therapeutics into the cytoplasm.14-17 This process thus circumvents 
the endo-lysosomal pathway3, 18 and leads to substantial enhancements in delivery 
efficiency.  
Aside from these highly desirable inherent properties of LDH that benefit cellular delivery, 
the particulate size is another key property that impacts the delivery efficiency. A few 
reports claim that nanoparticles with size ca. 50 nm are more efficiently internalised by a 
range of cell types, such as HeLa, Caco-2 and HT-29 cells.18-20 In particular, it was 
reported that LDH nanoparticles with a number-average size of 50 nm were the most 
efficient cellular delivery vehicles.18  
To date, LDH particles reported in most literature have a Z-average (or intensity-average) 
diameter ≥50 nm, even when hydrothermal treatment has been used in an attempt to tailor 
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and control the LDH particle size.21-23 Li et al.24 reported the so-called smallest CO3-LDH 
nanoparticles with a number-average size of ∼20 nm (observed in TEM) and an intensity 
average of ∼60 nm (measured with DLS). Using a non-aqueous precipitation method, 
Gardner et al.25 prepared a very well dispersed LDH suspension, and further Gunawan 
and Xu26 found that the number-average size of their as-prepared LDH particles was 30 
nm, while limited knowledge in relation to the growth mechanism has been reported.  
On the other hand, aggregation of LDH NPs in blood circulation is a big challenge for LDH 
applied as a perfect in vivo delivery vehicle. Liposomes are widely used biocompatible 
delivery tools in the recent decades because they are constituted by cell membrane 
components lipids, which are stable in blood circulation, especially after PEGylation. This 
projects aims to develop a composite system, which combines the advantages of LDH 
NPs and liposomes, with efficient cellular uptake, endosomal escape and good stability in 
blood circulation.  
Considering encapsulating LDH NPs in the liposomal vesicles, this chapter aims to 
decipher how small LDH NPs can be prepared using non-aqueous methodology through 
systematic investigation of effects of the experimental conditions on the particle size and 
the size distribution; and then sLDH growth mechanism is proposed.  
4.2 Experimental 
4.2.1 Materials preparation 
sLDH NPs were prepared by non-aqueous precipitation, followed by heat-treatment, 
purification and dispersion in water, which was modified from Pinnavaia’s method.25 
Typically, methanol solution (10 mL) of magnesium nitrate hexahydrate (Mg(NO3)2·6H2O, 6 
mmol) and aluminium nitrate nonahydrate (Al(NO3)3·9H2O, 2 mmol) was added dropwise 
to a methanol solution (40 mL) containing sodium hydroxide (NaOH, 16 mmol) under 
vigorous stirring. The mixture was stirred for 30-40 min, the precipitate slurry was then 
collected through centrifugation, redispersed in fresh methanol (40 mL) and transferred to 
a Teflon®-lined autoclave, followed by heat-treatment at 100 °C for 18 h. After cooling the 
sample to room temperature, the precipitate slurry was collected through centrifugation, 
and washed twice with deionised water (DI water). The final collected slurry was manually 
dispersed in 40 mL of DI water, followed by standing at room temperature with occasional 
hand-shaking. This dispersion became transparent, resulting in a homogeneous LDH 
suspension after 4-6 days with the LDH mass concentration determined to be 6 to 7 
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mg/mL (∼50% yield). A range of experimental factors, such as LDH mass concentration in 
the aqueous suspension (Conc6.5 to Conc29), methanol- (MW0 to MW2) and water-
washing (WW0 to WW2), the heat-treatment temperature (HT60 to HT100) and duration 
(HD4 to HD144), co-precipitation temperature with (CPT0HT to CPT50HT) and without 
hydrothermal treatment (CPT0 to CPT50), were varied to examine their influences on the 
average particle size and distribution, as summarised in Table 4-2. Note that all 
experiments were conducted in triplicate, and the standard deviation of triplicate 
experiments is shown.  
Large LDH nanoparticles (L-LDH NPs) were synthesised by vigorously mixing 10 mL of 
aqueous solution containing magnesium chloride hexahydrate (MgCl2·6H2O, 3.0 mmol) 
and aluminium chloride hexahydrate (AlCl3·6H2O, 1.0 mmol) with 40 mL of sodium 
hydroxide (NaOH) solution (0.15 M) for 10 min at room temperature.13, 27 The LDH slurry 
was collected by centrifugation and then washed twice with DI water (40 mL), and 
resuspended in DI water (40 mL), after which the suspension was transferred to a Teflon®-
lined autoclave and hydrothermally treated at 100 °C for 16 h. The suspension contained 
approximately 4 mg/mL of homogeneously dispersed Mg2Al-LDH nanoparticles, with a Z-
average particle size ~ 100 nm.13 
4.2.2 Materials characterisation 
The LDH NP size distribution in aqueous suspension was measured by dynamic light 
scattering (DLS) (also known as photon correlation spectroscopy, PCS) using a Zetasizer 
Nano ZS with three runs, from which an average of the Z-average size and the 
polydispersity index (PdI), also from three runs were calculated. Powder X-ray diffraction 
(XRD) patterns were recorded on a Rigaku Miniflex X-ray diffractometer with Co Kα source 
(λ = 0.1789 nm) at a scanning rate of 2.00° min-1 (2θ) from 2θ = 2° to 80°. Some XRD 
patterns were recorded on a thin film of LDH formed by dropping a few droplets of the LDH 
NP suspension and drying on a glass slide. FTIR spectra were obtained on a Nicolet 6700 
(Thermo Electron Corporation) by scanning 200 times from 4000 cm-1 to 400 cm-1 at a 
resolution of 1 cm-1. The morphology and size of some typical LDH NPs were examined by 
Transmission Electron Microscopy (TEM, JEOL 1011) at 80 kV. The concentrations of 
sLDH and large LDH suspension were calculated from magnesium and aluminium 
concentrations determined by ICP-AES (Varian VISTA AX Pro) in digested LDH NP 
solutions. The carbon, hydrogen and nitrogen composition in powdered LDH NPs were 
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analysed by an elemental analyser (FLASH EA 1112 series, Thermo Electron 
Corporation).  
4.3 Results 
4.3.1 Typical features of sLDH NPs 
As shown in Figure 4-1A, sLDH NPs typically possess a narrow particle size distribution. 
All nanoparticles are exclusively in the size range of 15-120 nm, with a Z-average diameter 
of 42 nm and polydispersity index (PdI) of 0.21. The TEM image (Figure 4-1B) indicates 
that these sLDH NPs maintain the well-established hexagonal nanosheet morphology, with 
the lateral dimension of most sheets in the range of 20-80 nm. Such sLDH nanoparticles 
are nearly half the size of those reported earlier, whose Z-average particle size was ≥ 80 
nm.22 Also of note is the fact that the number-average diameter of as-obtained sLDH 
nanoparticles is 21.4 nm, which is less than half that of the LDH particles (∼50 nm) 
reported by Oh et al.23 In comparison, the most widely reported to-date LDH particles 
prepared in aqueous solution had a Z-average size of 110 nm and a PdI of 0.22,22, 28 with 
an empirical formula Mg1.9Al(OH)5.8Cl0.8(CO3)0.1·1.5H2O as reported previously.29 
 
Figure 4-1 Particle size distribution (A) and TEM image (B) of typical sLDH suspension 
(prepared with 18 h of hydrothermal treatment at 100 °C; sLDH suspension droplet dried 
on carbon coated copper grid for TEM imaging) 
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 Figure 4-2 XRD pattern (A) and FTIR spectrum (B) of typical sLDH NPs (prepared with 18 
h of hydrothermal treatment at 100 °C; suspension dried as a thin film on glass slide for 
XRD characterisation) 
The XRD pattern (Figure 4-2A) shows that sLDH NPs possess the typical lamellar 
structure, as featured by reflections (003), (006) and (009) in the thin film mode.16 The d-
value was 0.79 nm, close to the reported value for Mg3Al-NO3-LDH (0.81 nm).16, 30 Note 
that the (003) reflection has a full width at half-maximum (FWHM) of 1.2°. This indicates 
that the thickness in the c-axis is ∼7 nm, nearly half the thickness of LDH prepared using 
the aqueous method.16, 27 This estimation has also revealed that the aspect ratio of as-
prepared sLDH was ∼6.  
The FTIR spectrum of sLDH (Figure 4-2B) is, as expected, largely identical to that of 
traditional Mg3Al-LDH,30 characteristic of the broad band at 3440 cm-1 (stretching 
vibrations of O-H in brucite-like layer and interlayer H2O molecules), the peak at 1637 cm-1 
(the bending vibration of interlayer and adsorbed H2O molecules), and the bands at 
around 591 cm-1 (M-O and M-O-H stretching vibrations).31 Of particular note is that the 
signal at 1358 cm-1, overlapping with the stretching vibration of NO3-,1, 30 is assigned to the 
stretching vibration of contaminant CO32-, which was likely captured from air during the 
preparation and drying processes. The element analysis (Mg/Al=2.9; 2.6 wt% N; 1.4 wt% 
C) gave an empirical formula of Mg2.9Al(OH)7.8(NO3)0.5(CH3O)0.2(CO3)0.1(OH)0.1·2.0H2O.  
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4.3.2 Parameters affecting LDH NP dispersion 
4.3.2.1 Effect of different LDH NP concentration on dispersion 
Figure 4-3A shows the change of Z-average particle size and polydispersity index (PdI) of 
sLDH NPs in suspensions with the duration of natural dispersion and the final sLDH 
concentration (Conc6.5-Conc29 in Table 4-2). After heat-treatment and water-washing, the 
collected precipitate was manually dispersed in deionised water (DI water), which was 
then left to stand at room temperature with occasional hand-shaking. The particle size 
distribution of this suspension was then measured daily. As shown in Figure 4-3A, after 4-
6 days of natural dispersion, the Z-average particle size of these sLDH NPs was stabilised 
at ∼45 nm. This size corresponds to the lateral size of the sLDH nanosheets (Figure 4-3B), 
thus revealing that individual sLDH nanosheets in suspension can be obtained after 4-6 
days of natural dispersion. A shorter period of dispersion resulted in a Z-average particle 
size of 100-200 nm (at day 1) and 45-65 nm (at day 2). The gradual reduction in Z-average 
particle size over time (day 1 to day 4) indicates that the aggregated precipitate is 
gradually becoming individually dispersed in DI water. Similarly, the PdI of as-obtained 
sLDH NPs in suspension reduced in line with the dispersion time (day 1 to day 4) and 
remained constant thereafter (Figure 4-3B). 
Data in Figure 4-3 seemingly indicates that the final sLDH concentration, which was 
achieved by dispersing water-washed sLDH slurry in a control volume of deionized water, 
has some influence on the dispersion state (PdI), but not the Z-average particle size. For 
example, the PdI was ∼0.42 at an sLDH concentration of 29 mg/mL, double the value 
(0.21) in the case of 6.5 mg/mL (Table 4-2 and Figure 4-3B). Although the Z-average 
sLDH particle sizes were 42-44 nm (Table 4-2) over the entire concentration range (6.5-29 
mg/mL), the variation of the Z-average particle size at a higher sLDH concentration was 
greater (error bar in Figure 4-3A and STDEV in Table 4-2). Both the higher PdI value and 
larger variation indicate there is some, albeit minor aggregation when higher sLDH 
concentrations are employed. In addition, the smaller number-average size at higher sLDH 
concentrations reveals that there is a greater population of much smaller LDH particles 
(around 10 nm) (Table 4-2, Conc29 generated smallest number-average size) in the high-
concentration suspension. 
Figure 4-4 shows the Z-average and polydispersity index (PdI) changes of sLDH NPs 
when the sLDH suspension was concentrated by incubation with calcium chloride in a 
enclosed chamber. Both the Z-average particle size and PdI increased gradually with the 
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sLDH suspension was concentrated. Therefore, this is not a proper way to concentrate the 
sLDH suspension. Instead, by dispersing sLDH slurry in lower volume of DI water, higher 
concentration of sLDH suspension with good particle size and acceptable polydispersity 
index will be obtained (Figure 4-3).  
 
Figure 4-3 sLDH NPs Z-average size (A) and polydispersity index (PdI, B) changes with 
dispersion time and concentration 
 
Figure 4-4 Z-average particle size and polydispersity index (PdI) changes of sLDH NPs 
when sLDH NP suspension was concentrated by calcium chloride 
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4.3.2.2 Effect of ultrasonication on sLDH NPs dispersion 
As is seen from Figure 4-5A, bath sonication helps to reduce the LDH particle size from 
more than 600 nm to around 200 nm when the LDH NPs were freshly prepared. While the 
sLDH NPs were well dispersed after ~ 4 days, there were no differences between the 
sLDH NPs with/out bath sonication treatment. As were the polydispersity index data 
(Figure 4-5B), bath sonication helped the sLDH NPs to be monodispersed in the 
beginning, but no big differences can be seen for the polydispersity index after the sLDH 
NPs were well dispersed after ~ 4 days.  
 
Figure 4-5 (A) Z-average particle size (A) and polydispersity index (PdI, B) changes of 
sLDH NPs with dispersion time and different bath sonication treatments 
4.3.2.3 Effect of methanol and water washing on dispersion 
Before and after heat-treatment, washing the collected sLDH slurry is a crucial step, which 
significantly affects the Z-average particle size, PdI as well as final product purity. We 
made three batches of sLDHs that differed merely in terms of the methanol washing time 
(0, 1, 2) before heat-treatment (MW0-MW2 in Table 4-2). As clearly shown in Figure 4-6A, 
washing twice with methanol led to the best dispersed suspension with the narrowest size 
distribution (44.8 nm, PdI of 0.20), while no washing gave a broader distribution with a 
significantly larger Z-average particle size (70 nm) and PdI (0.27), although the XRD 
patterns in Figure 4-6B demonstrate the similar crystallinity of these sLDHs.  
Similarly, the water-washing time (0, 1, 2) also significantly impacts the Z-average particle 
size and PdI (WW0-WW2 in Table 4-2). As shown in Figure 4-7A, the size of sLDH 
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particles (water washed twice, WW2) had a narrower distribution (PdI 0.21) and a smaller 
Z-average particle size (42.3 nm). When water-washing was omitted, only a small 
proportion of the collected sLDH aggregate was seen to disperse (WW0 in Figure 4-7A), 
which could be attributed to the presence of impurity salt NaNO3.22 The presence of this 
salt was confirmed by the sharp reflections in the XRD pattern (ICDD PDF card no. 36-
1474, WW0 in Figure 4-7B). 
Washing only once seemed to partially wash away the impure water-soluble salt NaNO3 
(although not detectable by XRD), which is likely responsible for the broad particle size 
distribution with a much larger Z-average size (Figure 4-7A and Table 4-2). The two small 
peaks around 2963 and 2850 cm-1 in FT-IR spectra (Figure 4-7C), attributed to C-H 
stretching vibrations of –CH3 in methoxide anion,32 was weakened after water-washing, 
indicating that water-washing also assists the removal of  methoxide from the sample, as 
is further explained below. 
 
Figure 4-6 Particle size distribution (A) and XRD patterns (B) of sLDH NPs from different 
methanol washing time(s): MW0, no methanol wash; MW1, methanol-washing once; MW2, 
methanol-washing twice 
The effect of methanol-washing seems to be largely masked by the subsequent water-
washing step. This is because the solubility of NaNO3 in water (0.911 g/mL at 25 °C) is 
much greater than that in methanol (0.00333 g/mL at 25 °C).33 Therefore it is reasonable 
to infer that water-washing twice removes all NaNO3 from our LDH slurry and only in the 
case where methanol wash was omitted (sample MW0 in Figure 4-6) did traces of salt 
remain, which could be responsible for incomplete dispersion. 
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Figure 4-7 Particle size distribution (A), XRD patterns (B), and FT-IR spectra (C) of sLDH 
NPs from different water washing time(s): WW0, no water wash; WW1, water-washing 
once; WW2, water-washing twice 
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4.3.3 Parameters affecting LDH NP size 
4.3.3.1 Hydrothermal treatment temperature and duration affect particle size 
Figure 4-8 and Figure 4-9 display the effects of heating temperature (60-100 °C) and 
duration (4-144 h) (over 15 days of natural dispersion) on the Z-average particle size and 
PdI of sLDH NPs. As shown in Figure 4-8A and B, when the treatment temperature was 
raised from 60 to 100 °C, the Z-average particle size and PdI change was only slight, from 
38 to 42 nm and 0.19 to 0.23 after 6 days of dispersion, respectively (HT60-HT100 in 
Table 4-2). Thus in general, the heat-treatment temperature had a limited impact on the 
sLDH particle size and distribution.  
 
Figure 4-8 sLDH NPs Z-average size (A) and polydispersity index (PdI, B) changes with 
dispersion time and hydrothermal treatment temperatures for 18 h 
In contrast, prolonging the heat treatment duration from 4 to 144 h at 100 °C increased the 
Z-average particle size from ∼39 to ∼47 nm while the PdI (0.19-0.22) remained unchanged 
after 6 days of dispersion (Figure 4-9A and B, HD4-HD144 in Table 4-2); this observation 
demonstrates that extending heating treatment time increased the particle size marginally.  
The limited effect of heating temperature and duration on the average particle size and 
distribution using methanol as solvent is in sharp contrast to that when water is used as 
solvent. As reported earlier by Oh et al 21 and Xu et al,22 the average LDH particle size can 
be tailored in a larger range (from 60-80 up to 300-400 nm) and the particle size 
distribution (PdI) increases from 0.2 to 0.5 during heating at 80-150 °C over 2-144 h. 
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Figure 4-9 sLDH NPs Z-average size (A) and polydispersity index (PdI, B) changes with 
dispersion time and hydrothermal treatment durations at 100 °C 
4.3.3.2 Tailoring particle size by controlling extended hydrothermal treatment 
durations 
Table 4-1 shows the Z-average particle sizes of original sLDH suspension and sLDH 
suspension after certain durations of further hydrothermal treatment at 100 °C after the 
sLDH NPs well dispersed at room temperature. Z-average particle size increased from 
42.05 nm to 57.11 nm and 73.05 nm after 2 and 4 days of extended hydrothermal 
treatment, increased by 35.81% and 73.72% (Table 4-1). While after 4 days, it seemed 
that the particle size growth rate slowed down. The mechanism for particle size growth 
during hydrothermal treatment will be discussed in 4.4 Discussion of sLDH NPs formation 
mechanism.  
4.3.3.3 Co-precipitation temperature affects particle size 
The co-precipitation step was trialled at temperatures of 0, 23 and 50 ºC by mixing the salt 
methanol solution with the basic methanol solution. Both solutions were pre-cooled to 0 ºC 
or pre-heated to 50 ºC before mixing. Stirring was conducted throughout the co-
precipitation process and continued for 30 min at the same temperature, followed by 
methanol washing, heat-treatment at 100 °C for 18 h, and deionised water washing twice 
(CPT0HT to CPT50HT in Table 4-2). As shown Figure 4-10A and listed in Table 4-2, co-
precipitation at 0 and 23 °C yielded sLDH NPs of the similar size with minor fluctuations in 
their size distribution (44.3 and 42.3 nm with a PdI 0.25 and 0.21), while co-precipitation at 
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50 ºC generated a slightly larger particles (50.5 nm), indicating that the co-precipitation 
temperature has a marginal effect on the sLDH NP size.  
Table 4-1 Z-average particle size and polydispersity index changes of sLDH NPs with 
further hydrothermal treatment after well dispersed at room temperature 
Further hydrothermal treatment 
durations at 100 °C 
Z-Average 
(d.nm) 
Z-average 
increase 
Polydispersity 
index 
Size Peak 
(d.nm) 
0 d 42.05 / 0.235 43.75 
2 d 57.11 35.81% 0.160 68.16 
4 d 73.05 73.72% 0.167 85.17 
6 d 77.03 83.19% 0.171 88.86 
8 d 80.93 92.46% 0.136 94.85 
 
Figure 4-10 Particle size distribution of sLDH NPs prepared at different coprecipitation 
temperatures followed by hydrothermal treatment at 100 °C for 18 h (A) and without 
hydrothermal treatment (B) 
Furthermore, if heat-treatment was omitted (Figure 4-10B, CPT0 to CPT50 in Table 4-2), 
the resultant LDH NPs had a smaller Z-average size than those heat-treated. In particular, 
co-precipitation at 0 °C led to the smallest sLDH size (35.0 nm) with a narrower size 
distribution (0.21) compared to those at 23 and 50 °C (size of ∼40 nm with PdI of ∼0.24).  
It is worth noting that once prepared, the homogeneous dispersion remained stable for 
more than one month, regardless of whether the sample was stored at fridge temperature 
(2-8 °C) or room temperature (22-25 °C) (Figure 4-11). 
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Figure 4-11 sLDH suspension stability study stored at ambient (room) temperature (RT) or 
fridge temperature (2~8 °C) (FT) 
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4.3.3.4 Compositions of LDH NPs affect particle size 
As shown in Table 4-3, MgAl-Cl LDH NPs prepared by non-aqueous method can be well 
dispersed after 2-3 days of standing at room temperature, while the MgAl-Cl LDH particle 
size (> 60 nm) is much bigger than the normal MgAl-NO3 sLDH (~ 40 nm). This is due to 
the ion radius differences between Cl- (0.181 nm) and NO3- (0.129 nm).  
Table 4-3 Particle size and polydispersity index (PdI) changes of MgAl-Cl LDH prepared 
by non-aqueous method with dispersion time 
Dispersion time 
Z-Average 
(d.nm) 
PdI 
Intensity Mean 
(d.nm) 
Number Mean 
(d.nm) 
Volume Mean 
(d.nm) 
Size Peak 
(d.nm) 
0 h 874.6 0.506 1520 217.1 1981 1516 
12 h 241.5 0.974 998.0 24.16 342.0 1350 
1 d 80.10 0.286 215.1 35.43 110.1 114.9 
2 d 61.71 0.205 78.71 8.622 25.62 79.19 
3 d 63.09 0.179 77.71 19.68 38.79 77.71 
Figure 4-12 shows the Z-average particle size and PdI changes of LDH NPs with 
dispersion time and different magnesium to aluminium ratios with/out hydrothermal 
treatment. Both magnesium to aluminium ratios of 2 and 4 gave much larger particle sizes 
regardless of hydrothermal treatment or not. No much differences can be seen for the 
polydispersity index data, and they were all in acceptable range (~ 0.20, Figure 4-12B) 
after 4~6 days of natural dispersion. The good dispersion state of sLDH NPs with 
magnesium to aluminium ratio of 3 could be attributed to the specific surface charge 
density. 
Figure 4-13 shows the Z-average particle size and polydispersity index changes of LDH 
NPs prepared by non-aqueous method with Co/Ni/Zn-Al at different ratios with/out 
hydrothermal treatment. All these LDH NPs show much larger particle sizes than the 
Mg3Al-sLDH (LDH NPs with Co exhibit particle size ~ 100 nm, smaller than those with Ni 
or Zn. Moreover, most of these LDH NPs show much bigger polydispersity index, which 
mean poor dispersion state. 
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Figure 4-12 Z-average particle size (A) and polydispersity index (PdI, B) change of LDH 
NPs with dispersion time (LDH NPs prepared by non-aqueous method with different 
magnesium to aluminium ratios) 
 
Figure 4-13 Z-average particle size (A) and polydispersity index (PdI, B) changes of LDH 
NPs with dispersion time (LDH NPs prepared by non-aqueous method with Co, Ni, Zn and 
different divalent elements to trivalent elements ratios) 
Figure 4-14 shows the Z-average particle size and polydispersity index changes of LDH 
NPs prepared by non-aqueous method with FeAl-Cl and MgFe-Cl at different ratios without 
hydrothermal treatment. All these LDH NPs also show particle sizes larger than 100 nm 
and polydispersity index around or more than 0.2.  
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Figure 4-14 Z-average particle size (A) and polydispersity index (PdI, B) changes of LDH 
NPs with dispersion time (LDH NPs prepared by non-aqueous method with FeAl-Cl and 
MgFe-Cl at different divalent elements to trivalent elements ratios) 
4.4 Discussion of sLDH NPs formation mechanism 
In summary, non-aqueous preparation, involving co-precipitation and heat-treatment in 
methanol, and then dispersion in deionised water for 4-6 days, generally produces much 
smaller LDH NPs that can be individually dispersed into homogeneous aqueous 
suspensions. Our investigations indicate that the co-precipitation temperature, heating 
temperature and duration have marginal influences on the Z-average particle size of 
homogenously dispersed sLDH NPs (i.e. the sLDH crystals). Other factors, such as 
methanol washing, water washing, the duration of natural dispersion and sLDH mass 
concentration in the final aqueous suspension, merely affect the dispersity of sLDH NPs in 
suspensions. 
It is suggested that when the mixed salts are added into basic methanol solution, the 
following precipitation takes place to generate LDH nuclei, as in the aqueous case: 
(1) 
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Table 4-4 XRD lattice and FWHM depending on methanol- and water-washing procedure 
Sample label c (nm) a (nm) FWHM (degree) 
MW0 2.414 0.304 2.02 
MW1 2.463 0.304 1.94 
MW2 2.363 0.306 1.82 
    
WW0 2.751 0.306 2.30 
WW1 2.609 0.306 2.00 
WW2 2.465 0.304 2.00 
    
HT144 2.444 0.304 1.22 
CPT0 2.459 0.306 1.54 
Following nucleation, nuclei are normally aged at a pre-determined temperature for a given 
period of time to enable them to disperse and grow into large crystallites. As reported 
elsewhere, in the case where water is employed as the solvent, the heat treatment can 
increase the LDH particle size by a factor of 3-5. For example, the particle size can grow 
from ∼90 to ∼280 nm (Z-average particle size) upon heat treatment at 100 °C from 4 to 144 
h, and from ∼90 to ∼190 nm when heated at temperatures for 16 h at 80 to 150 °C.27 In 
other reports (where the size was reported as a number-average value), LDH particle size 
can be tailored from ∼85 to ∼120 nm when heated at 100 °C from 12 to 72 h, from ∼115 to 
∼340 nm when heated for 48 h at 100 to 180 °C 21 and from ∼50 to ∼350 nm when heated 
at 100-200 °C for 12-48 h.18 In this research, however, where methanol was employed as 
the solvent, the sLDH Z-average particle size was increased only slightly from 39 from 47 
nm when heated at 100 °C from 4 to 144 h, i.e. 20-30% increase. More strikingly, there 
was only a 10% variation (38-42 nm) in the Z-average particle size when heated from 60 to 
100 °C for 18 h. The sharp contrast in MgAl-LDH crystallite growth behaviours in methanol 
and water could be largely attributed to the solubility differences of MgAl-LDH in the two 
solvents.  
During heat treatment, the so-called Ostwald ripening process occurs, i.e. large crystallites 
grow at the expense of small crystallites, primarily due to the higher solubility of small 
crystallites in the same solvent as a result of their higher surface energy and specific 
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surface area. Moreover, such a dissolution/recrystallisation process is highly dependent on 
the solubility of LDH in that solvent. As reported previously,18 the solubility of MgAl-Cl-LDH 
and MgAl-CO3-LDH in water is 110 and 40 mg/L, respectively, which is consistent with our 
finding that as-prepared large MgAl-NO3-LDH possesses a solubility of ∼100 mg/L in water 
at 23 °C. In contrast, we noted the solubility of MgAl-LDH in methanol is only 5-10 mg/L at 
23 °C. Therefore, as-formed LDH crystallites are considerably less soluble in methanol 
than in water. If we suppose that the solubility difference between large and small LDHs in 
methanol or water is proportional to the solubility in methanol or water, then the growth 
rate of LDH crystallites in methanol would be much slower than that in water under 
identical conditions, which would explain why the Z-average particle size is not very 
sensitive to variation in heating temperature and duration in methanol. This may mean that 
the size of as-prepared sLDH is largely dependent on the size of LDH nuclei formed in 
methanol. This hypothesis is further supported by the data in Table 4-2 that the Z-average 
size and PdI of sample CPT23 (without heat-treatment, 38.6 nm and 0.23) were very 
similar to those of samples HT60-HT100 (with heat treatment at 60-100 °C for 18 h, 38-42 
nm and 0.19-0.23). Nonetheless, 144 h heating treatment gave better crystallinity (sample 
HD144), as reflected by the smaller full width at half maximum (FWHM) value (1.22° for 
003 reflection, Table 4-4) than that of CPT0 (FWHM = 1.54°) without heat-treatment. 
Given this relationship, engineering sLDH without any heat treatment and with co-
precipitation at 0 °C would be most desirable. This process indeed led to the smallest LDH 
with the Z-average particle size of 35.0 nm and PdI of 0.21 (CPT0 in Table 4-2) in this 
research. 
The dispersion of as-formed sLDH NPs in aqueous suspension can be tightly correlated to 
temperature as well as impure salt presence and concentration. As reported previously,22, 
27 hydrothermal treatment of manually dispersed LDH aggregates in water at 80-150 °C 
results in a well-dispersed LDH suspension; this could be attributed to hydrothermal 
heating, which provides enough thermal energy for some LDH particles to detach from an 
aggregate and become suspended in the solution. As all LDH NPs carry a positive charge 
(zeta potential 40-50 mV),3, 13 so the repulsion between LDH nanoparticles is then 
expected to keep them stably suspended in solution once disaggregation has occurred. As 
explained above, the existence of NaNO3 in the current system prohibits complete 
dispersion of sLDH; this is primarily due to electrolyte ions reducing the thickness of 
electric double layers, which act as the ‘glue’ between particles.34, 35 We also gather from 
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previous experiments that LDH particles will no longer disperse when the electrolyte 
concentration reaches a threshold value, for example, at 0.1-0.2 M of NaCl.  
In this research, the dispersion of sLDH NPs was conducted at room temperature, without 
the assistance of heat. Normally 4-6 days of standing with occasional hand-shaking gives 
rise to a complete dispersion of sLDH NPs in solution. Achieving a relatively small particle 
size (40-50 nm) is a central aim of this research, and the thermal energy at room 
temperature is considered sufficient to de-aggregate sLDH NPs from the aggregates. A 
plausible reason for the smaller particle dispersion could be related to the following 
exchange reaction occurring during the dispersion process: 
OHxCHOnHOHNOOHAlMg
OHmxnOmHOHNOOCHOHAlMg
yy
yxyx
321383
2213383
)()()(
)()()()()(
+⋅
→−++⋅
−
−−        (2) 
This reaction likely takes place when the LDH slurry is washed with water. As shown in 
Figure 4-7C, the IR peak intensity of methoxide C-H vibrations decreased from sample 
WW0 to WW2, indicating that CH3O- is gradually eliminated from the interlayer upon water 
washing. The replacement of a somewhat bulky methoxide by smaller OH-/NO3- ions is 
also reflected by decrease in the interlayer distance from WW0 (c/3, e.g. 0.92 nm) to WW2 
(0.82 nm) (Table 4-4). This is also consistent with the reduction of carbon weight 
percentage from sample WW0 (2.50 wt %, Table 4-5) to WW2 (1.41 wt %, when more 
CH3OH is washed out). It is our belief that the occurrence of this exchange reaction 
facilitates sLDH dispersion, although this remains under close investigation. 
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4.5 Conclusions 
sLDH particles engineered by this non-aqueous approach possess a Z-average diameter 
size of 35 to 50 nm, albeit with heat treatment temperatures ranging from 60 to 100 °C and 
treatment duration up to 144 h, yielding a final sLDH suspension concentration of 6.5-29 
mg/mL. Co-precipitation at 0 °C without hydrothermal treatment will generate smallest 
particle size. Removing salt impurities prior to natural dispersion proves crucial for 
homogeneous particle dispersion with a narrow particle size distribution. Ultrasonication 
treatment can reduce the LDH particle size of freshly prepared NPs, but will not affect the 
final particle size. Once prepared the physical characteristics of our sLDH nanoparticles 
remain as are, for at least one month. Controlled size of LDH NPs can be obtained by 
further hydrothermally treating the well-dispersed sLDH NPs.  
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Chapter 5 Particle Size- and Number-dependent 
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Abstract 
It is well known that delivery efficiency to cells is highly dependent on the particle size and 
the dose used in the experiments. However, there is a marked discrepancy in many 
reports, mainly due to the inconsistence in assessment of various parameters. In this 
chapter, we designed specific experiments using layered double hydroxide nanoparticles 
(LDH NPs) to elucidate the effect of particle size, dose and dye loading manner on the 
cellular uptake. Using the number of LDH NPs taken up by HCT-116 cells as the indicator 
of delivery efficiency, we found that (1) the size of sheet-like LDH in the range of 40-100 
nm did not significantly affect their cellular uptake; (2) cellular uptake of 40 and 100 nm 
LDH NPs was increased proportionally to the number concentration below a critical value, 
but kept nearly unchanged beyond the critical value; and (3) the effect of the dye loading 
manner is mainly dependent on the loading capacity or yield. In particular, the loading 
capacity is determined by the NP specific surface area. This research may be extended to 
a larger size range to examine the size effect, but suggests that it is necessary to set up a 
protocol to evaluate the effects of NP’s physicochemical properties on the cellular delivery 
efficiency. 
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5.1 Introduction 
Recent years have witnessed the enormous progress of nano-sized materials 
applied for drug/gene delivery, which include various polymeric nanoparticles (NPs), 
liposomes, metal (such as gold) and metal oxide (such as iron oxide, IO) NPs, 
mesoporous silica NPs (MSNs), carbon nanotubes (CNTs), layered double 
hydroxide (LDH) NPs, and their hybrids etc. 1-16  
It is well known that the physicochemical properties, such as the NP size, shape, dose and 
surface charge, affect the NP delivery efficacy. Of these characteristics, the particle size is 
a crucial factor which determines NP endocytosis pathway,17, 18 uptake rate and 
efficiency,6, 16, 19-22 in vitro cytotoxicity,23-28 immune responses,28-31 and the final 
localisation.15, 32, 33 Thus size-dependent uptake of various NPs has been intensively 
investigated and widely reported. For example, for organic NPs, some researchers 
claimed smaller NPs resulted in higher cellular uptake,22, 34 while others reported an 
optimal size range for highest uptake.35-38 Ross and Hui39 even found linearly increasing 
cellular uptake of lipoplex in the size range of 35 to 2200 nm. For inorganic-based NPs, 
the similar results were reported. Some researchers reported an optimal particle size for 
uptake of Au NPs, CNTs, and MSNs (~ 50 nm),6, 40-42 but some others found smaller Au, 
silica, and IO NPs had improved cellular uptake than larger ones in a certain size range.43-
46  
Besides the particle size, the NP shape, on the other hand, also affects the cellular uptake 
behaviours. Chithrani et al.6 reported HeLa cells took up much more spherical Au NPs 
than rod-shaped Au NPs with a high aspect ratio. Jin et al.41 found long and short SWNTs 
showed lower cellular uptake than those with the medium length. Choi and Choy’s group 
studied the cellular uptake behaviours and mechanisms of LDH NPs (with sheet-like 
shape), finding 50 nm LDH NPs showed higher cellular uptake than 100-200 nm and 350 
nm ones.47, 48 Recently we found 40 nm LDH NPs can carry 1-4 times more dsDNA than 
100 nm ones at LDH:DNA mass ratio of 1:1 and 5:1, contributing to enhanced gene 
delivery.49, 50  
In brief, the observations and conclusions differ from research groups, especially the 
particle size effect, being not so consistent and sometimes confused. This could be 
caused by several vague items without clear and consistent definition. The first one is the 
NP size, which is normally characterised as the Z-average hydrodynamic diameter 
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(measured by dynamic light scattering technology)29, 42, 51 or the number average size 
(measured and statistically calculated from transmission/scanning electron microscopy 
images).6, 28 The second term is the dose of nanoparticles. Someone used the mass 
concentration while some others used the particle number concentration. The third one is 
the delivery efficiency, often expressed as the NP number,6, 16, 44, 52 the mass amount 
(pg/cell),16, 42 or the relative amount of labelled fluorescence dye49, 53 taken up by each cell. 
In addition, the difference in the shape and surface property from a variety of materials and 
surface modified functional groups may also cause the inconsistence. It is worth noting 
that the cell type used in different research groups is often different, which may also 
contribute to the inconsistence in determining the optimal particle size for the maximum 
cellular uptake efficiency. 
Therefore, this particular research aimed to clearly elucidate effects of the particle size (Z-
average), the dose (particle number concentration) and the dye loading (bulky or surface) 
of sheet-like LDH NPs on the uptake efficiency by HCT-116 cells. We found that (1) the 
cellular uptake efficiency of 40-50 nm NPs was similar to that of 90-100 nm NPs; (2) there 
was a critical particle number concentration, below which cellular uptake was in linear 
proportion to the particle number concentration, while beyond which cellular uptake was 
not improved; (3) dye loading on the surface may also affect cellular uptake depending on 
the surface loading capacity. 
5.2 Experimental  
5.2.1 LDH NPs preparation 
Small LDH (sLDH) NPs were prepared by a non-aqueous precipitation method.49, 50 
Briefly, 10 mL methanol solution containing 6 mmol of Mg(NO3)2·6H2O and 2 mmol 
of Al(NO3)3·9H2O was added drop-wise to a 40 mL of methanol solution containing 
16 mmol NaOH under vigorous stirring. The precipitate slurry was collected via 
centrifugation, then redispersed in 40 mL fresh methanol and transferred to a 
Teflon®-lined autoclave for heat-treatment at 100°C for 4 h. The final LDH slurry 
was collected and manually dispersed in 40 mL of deionised water (DI water) after 
washing twice with DI water. This dispersion resulted in a homogeneous sLDH 
suspension after 4-6 days with a sLDH mass concentration of 6-7 mg/mL. 
Large LDH (L-LDH) NPs were synthesised by mixing 10 mL of aqueous solution 
containing 3.0 mmol of MgCl2·6H2O and 1.0 mmol of AlCl3·6H2O  with 40 mL of 0.15 
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M NaOH solution and vigorously stirring for 10 min at room temperature 54, 55. The 
LDH slurry was collected by centrifugation, washed twice with DI water (40 mL), and 
then resuspended in DI water (40 mL). The suspension was then transferred to a 
Teflon®-lined autoclave and hydrothermally treated at 100°C for 16 h. The 
suspension contained approximately 4 mg/mL of homogeneously dispersed L-LDH 
NPs. 
Both small and large LDH-FITC NPs were prepared by ion-exchange method. Here, 
FITC (fluorescein isothiocyanate isomer I) sodium solution (0.05 or 0.01 mmol) was 
mixed with 1 mmol of either sLDH or L-LDH slurry and then shaken on a reciprocal 
shaker for 1 h. After ion-exchange, the unchanged FITC and residual sodium nitrate 
or sodium chloride (NaNO3/NaCl) were separated. The collected slurry was then 
redispersed in deionised water and subjected to 2-4 h of hydrothermal and 
sterilisation treatment.  
All NP sizes were determined by dynamic light scattering (DLS, Zetasizer Nano ZS, 
Malvern Ltd). The Z-average size of sLDH was found to be ~40 nm (~54 nm for 
sLDH-FITC), while L-LDH measured ~100 nm (~90 nm for L-LDH-FITC).   
5.2.2 Suspension stability test 
LDH NPs were diluted by complete cell culture media (10% (v/v) of fetal bovine 
serum mixed with Dulbecco’s Modified Eagle Medium (DMEM, with L-glutamine and 
4.5 g/L of glucose) at desired concentrations, then particle size distribution of the 
suspension mixture was measured using the zetasizer.  
5.2.3 Nucleic acid loading and agarose gel electrophoresis 
Nucleic acids were loaded on LDH NPs by mixing LDH suspension with nucleic acid 
solution at the LDH:dsDNA mass ratios of 2:1, 5:1, 10:1, 20:1, and 40:1. A 2.5% 
agarose gel with Gel-Red stain was made and then nucleic acids with/out LDH for 
binding were loaded in the wells. For each well, 260 ng double stranded DNA 
(dsDNA DCC1) was used. Gel was imaged by a Bio-Rad imaging system after run 
at 90 V for 45 min in TBE (Tris/Borate/EDTA) buffer. 
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5.2.4 Cellular uptake 
HCT-116 cells were seeded in 6-well plates at density of 1×105 cells per well in 2 
mL complete cell culture media. After 24 h of incubation, cell culture media was 
replaced by 1 mL of fresh media with/out desired concentration of LDH-FITC NPs or 
LDH-DNA-Cy3 NPs (40 nM DNA was used). At different time points after further 
incubation (from 15 min to 8 h), the culture media was removed, cells were washed 
twice with PBS buffer and then detached from the plates by trypsin-EDTA. The cells 
were washed twice with PBS buffer and then fixed in a certain volume of 2% PFA 
(paraformaldehyde) before measurement by flow cytometry (BD Accuri™ C6 Flow 
Cytometer System, band pass filter 530/30 for detecting FITC, 585/40 for detecting 
Cy3, 10,000 cells were counted). All treatments were performed for three different 
batches in duplicate. Data are presented as the mean ± SEM (standard error of the 
mean).  
5.3 Results 
5.3.1 System suspension stability 
As shown in Figure 5-1, both sLDH and L-LDH NPs are well dispersed in water, having a 
hydrodynamic diameter ranging from 10 to 100 nm with the Z-average size of 40 nm, and 
from 40 to 250 nm with the Z-average size of 100 nm, respectively. Both sLDH and L-LDH 
NPs have a zeta potential of ~40 mV, which is in agreement with earlier reports for LDH.49, 
55, 56  
When LDH NPs were diluted in complete cell culture media, both sLDH and L-LDH NPs 
aggregated, and this was found to be concentration- and size-dependent. As shown in 
Figure 5-2, when the sLDH NP suspension was diluted to a concentration range of 100-
800 µg/mL, sLDH formed aggregates with the Z-average size of 200-450 nm. Applying the 
same concentration range to L-LDH NPs, they also aggregated but to a less extent, with 
the Z-average size of 180-300 nm. The Z-average size (74 and 107 nm) was in close 
agreement with that in the original suspension for both sLDH and L-LDH when they were 
further diluted to 40 µg/mL. The aggregation may affect the cellular uptake as Andersson 
et al.57 found NP uptake was strongly dependent on the agglomeration size, not the 
primary particle size. This proved serendipitous as the concentration of LDH NPs used in 
cellular uptake studies did not typically exceed 40 µg/mL so as to circumvent unwanted NP 
aggregation. 
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Figure 5-1 Particle size distribution of small and large LDH 
 
Figure 5-2 Particle size distribution of sLDH and sLDH in cell culture media 
Particle aggregation was more pronounced with sLDH in the culture media and this could 
be attributed to their relative dimensions compared to L-LDH. sLDH possesses a surface 
area 2.5 times that of L-LDH NPs, and thus its capacity to adsorb proteins (a key driver of 
aggregation) present in cell culture media is also considered to be 2.5-fold greater than L-
LDH. Upon lowering the NP concentration sufficiently (i.e. < 40 µg/mL), sLDH and L-LDH 
NPs adsorb protein until they reach a relative state of equilibrium, at which point their 
surface properties are dictated by adsorbed proteins such that aggregation is suppressed. 
That said, at high NP concentrations, one can expect to reach a point where all available 
proteins are adsorbed by the NPs, and this triggers surface adsorbed proteins to reach out 
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and form protein-bridges with neighbouring particles, resulting in aggregation. This latter 
phenomenon is likely to be more of an issue with sLDH, as L-LDH possesses a smaller 
surface area and so is able to accommodate far less proteins. 
5.3.2 DNA loading 
Figure 5-3 to Figure 5-4 show the electrophoretic mobility of dsDNA loaded onto LDH NPs 
at increasing LDH:dsDNA mass ratios. The first lane for each gel represents a 21-25 bp 
dsDNA marker, and the bright bands toward the bottom of the gels are free dsDNA. As 
can be seen in Figure 5-3A, sLDH NPs completely immobilised dsDNA at the mass ratio of 
≥ 5:1 in water, while at 2:1 some free dsDNA was present. Similarly, L-LDH NPs 
completely bound dsDNA at the mass ratio of ≥ 10:1 in water, while the binding was not 
complete at 5:1 (Figure 5-3B). This difference can again be attributed to the particle size 
as the larger surface area of sLDH NPs can accommodate a greater load of dsDNA as 
compared to L-LDH NPs at the equivalent mass concentration.  
 
Figure 5-3 Agarose gel electrophoresis test of sLDH (A) and L-LDH (B) loading dsDNA in 
water at different mass ratios (260 ng dsDNA used, 2.5 % agarose gel run at 90 V for 45 
min) 
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When the LDH-dsDNA complexes were assessed in complete cell culture media, 
electrophoretic studies revealed less dsDNA immobilised (Figure 5-4) than that in water 
(Figure 5-3). In the complete cell culture media, only at mass ratios of 20:1 and 40:1 was 
dsDNA observed to be completely bound by both sLDH and L-LDH NPs. However, the 
surface area of the respective NPs again yielded subtle differences in binding with dsDNA 
at the lower (e.g. 5:1) mass ratios.  
As alluded to earlier, the significant differences in mass ratios necessary to completely 
immobilise dsDNA in water versus complete cell culture media can once again be 
attributed to the competitive adsorption of proteins (in serum) onto the respective NP 
surfaces. This competition results in a relatively higher mass of LDH NPs needed to fully 
complex dsDNA in complete cell culture media, and is a phenomenon seen with other 
vector-DNA complexation studies.58  
 
Figure 5-4 Agarose gel electrophoresis test of sLDH (A) and L-LDH (B) loading dsDNA in 
cell culture media at different mass ratios (260 ng dsDNA used, 2.5 % agarose gel run at 
90 V for 45 min) 
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5.3.3 Cellular uptake 
5.3.3.1 LDH-FITC uptake 
We first tested the cellular uptake of FITC-labelled NPs at different LDH 
concentrations by HCT-116 cells. The FITC loading capacity within both types of 
LDH NPs was comparable, being 5% of all intercalated anions (denoted as LDH-
5%FITC). We found that > 99% of cells were FITC-positive after incubation with 
either sLDH-5%FITC or L-LDH-5%FITC at 4 h, and across the concentrations 
measured (2.5 to 20 µg/mL) (Figure 5-5A and B). The mean fluorescence intensity 
of cells treated with sLDH-5%FITC at these concentrations did not change (≥ 5.0 
µg/mL), indicating that the cellular uptake was saturated under these conditions. 
Our previous confocal images have confirmed that hexagonal LDH NPs are taken 
up by various cell types and mostly located in the cytoplasm.49, 55, 59, 60  
 
Figure 5-5 Cellular uptake of small (A) and large (B) LDH-5%FITC by HCT-116 cells at 
concentration of 2.5 to 20 µg/mL 
In sharp contrast, the mean fluorescence intensity of cells treated with L-LDH-5%FITC 
exhibited increasing fluorescence intensity as the LDH concentration was raised (Figure 
5-6); this reveals that the cellular uptake of L-LDH-5%FITC continued under the same 
conditions albeit at a declining rate, indicating the saturated particle concentration for L-
LDH-5%FITC is most likely in the region of 20 µg/mL. For sLDH, at the concentration of 
1.4 µg/mL, the mean fluorescence intensity was quite low, showing a strong dependence 
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on the sLDH mass concentration, similar to the dependence seen by L-LDH at 2.5-20 
µg/mL (Figure 5-6). Choy et al.11 also found dose dependent uptake of LDH-FITC NPs by 
NIH 3T3 cells in the test concentration range (< 45 µM). Li et al.51 reported concentration 
dependent uptake of 65 nm CO3LDH-FITC by NSC 34 cells in the concentration range of 
6.25 to 100 µg/mL, where FITC was adsorbed on the surface of CO3LDH instead of 
intercalated into the interlayers.  
 
Figure 5-6 Mean FITC intensity in the cells treated by small and Large LDH-FITC NPs at 
concentration of 1.4 to 20 µg/mL 
To explore LDH-5%FITC cell uptake kinetics, time-dependent uptake of small and large 
LDH-5%FITC at 1.4 and 10.0 µg/mL was investigated. Figure 5-7A shows that almost all 
cells treated with 1.4 µg/mL of L-LDH-5%FITC were FITC-positive after ≥2 h, although the 
mean FITC fluorescence intensity kept increasing with incubation time (Figure 5-7B). In 
comparison, only 25-35% cells were FITC-positive with the mean FITC fluorescence 
intensity nearly constant when treated with sLDH-FITC at this concentration for ≥ 2 h. Of 
note was that the mean fluorescence intensity of cells treated with L-LDH was 15-20 times 
that of sLDH, after 2-8 h of incubation.  
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Figure 5-7 Cellular uptake of small and large LDH-FITC at concentration of 1.4 µg/mL  
In the case of 10 µg/mL of FITC-labelled LDH NPs, almost all cells were FITC-positive 
upon treatment with both small and large LDH-5%FITC NPs (Figure 5-8A) after 4 h of 
incubation. During the 15 min to 4 h incubation window L-LDH-5%FITC led to a marginally 
higher percentage of FITC-positive cells. This is comparable to what Li et al. 56 reported, 
where 60-70% of positive cells were observed after incubating MDDC cells with 20 µg/mL 
FITC-labelled LDH NPs (hydrodynamic number size ∼60 nm). The mean FITC intensity 
continuously increased during the whole uptake process with both sets of NPs (Figure 
5-8B). Such a time-dependent uptake of LDH-FITC NPs by NIH 3T3 cells was also 
reported by Choy et al.11 Interestingly, the mean FITC fluorescence intensity of the cells 
treated with 10 µg/mL of L-LDH-5%FITC appeared to be 2-3 times that of the cells treated 
with 10 µg/mL of sLDH-FITC at each time point. 
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Figure 5-8 Uptake of small and large LDH-FITC at concentration of 10 µg/mL 
To elucidate specifically the role of NP size on the rate and efficiency of cellular uptake, we 
particularly prepared L-LDH NPs containing 1% FITC (L-LDH-1%FITC, ∼90 nm) and 
compared the cellular uptake at 20 µg/mL of L-LDH-1%FITC and 4 µg/mL of sLDH-
5%FITC (both being close to saturated particle concentration as discussed earlier). In this 
series of experiments, each FITC-labelled NP contained an equivalent amount of FITC 
and the NP number concentration was also the same. Thus, assessment of cellular uptake 
efficiency would be reflected purely from a NP-size perspective. As shown in Figure 5-9, 
similar FITC-positive cell percentage and mean FITC intensity were observed in both 
cases. The subtle difference is that cellular uptake efficiency equilibrated after 2 h of 
incubation with sLDH-FITC, while L-LDH-FITC NPs uptake kept increasing over the same 
period, as measured by the percentage of FITC-positive cells and mean FITC 
fluorescence intensity. This probably reflected a more rapid uptake of sLDH-FITC NPs 
before 4 h, but sustained and continuous uptake of L-LDH-FITC NPs after 4 h. Rapid 
internalisation of 50 and 100 nm spheric NPs compared to 200 nm ones was also reported 
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by Rejman et al.18 More interestingly, the continuous uptake of larger NPs was also 
observed and reported for viral NPs,61 polyplexes,62 and lipoplexes.63  
 
Figure 5-9 Time course cellular uptake of small and large LDH-FITC at identical particle 
number concentration and FITC loading 
5.3.3.2 DNA uptake 
We next investigated the cellular uptake of LDH-DNA complexes, where DNA was 
predominantly adsorbed on the LDH NP surface.49, 60 The loading capacity of DNA onto 
LDH was determined by varying the LDH: DNA mass ratios, as discussed previously 
(Figure 5-3 and Figure 5-4). Based on the observations in Figure 5-3 and Figure 5-4, we 
chose two LDH: DNA mass ratios, the first of which reflected incomplete LDH-DNA 
complexation (5:1) while the second reflected complete complexation (40:1), irrespective 
of NP size. The time-dependent cellular uptake of both sets of LDH NPs with DNA-Cy3 is 
presented in Figure 5-10 to Figure 5-11.  
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Figure 5-10 Cellular uptake time course of LDH-DNA at mass ratio of 5:1 by HCT-116 cells 
At the mass ratio of 5:1 (40 nM DNA-Cy3 and 1.4 µg/mL sLDH), the percentage of Cy3-
positive cells quickly increased to 60% after just 2 h incubation, and then slowly increased 
to 80% over the next 6 h. However, in the case of L-LDH-DNA-Cy3, the percentage of 
Cy3-positive cells increased steadily over the entire incubation period, reaching a mere 
20% after 8 h incubation (Figure 5-10A). The mean Cy3 fluorescence intensity followed a 
similar trend (Figure 5-10B). Our findings are consistent with our previous observation in 
HEK-293T cells,50 suggesting that partial complexation of DNA by L-LDH NPs at this mass 
ratio is detrimental to gene delivery efficiency. This observation seems to be similar to the 
report by Elbakry et al.64 that far more DNA molecules were delivered to one cell by 20 nm 
Au NPs than 80 ones.  
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Figure 5-11 Cellular uptake time course of LDH-DNA at mass ratio of 40:1 by HCT-116 
cells 
At the mass ratio of 40:1 (40 nM DNA-Cy3 and 11 µg/mL LDH), treatment with sLDH and 
L-LDH led to a similar population of Cy3-positive cells after 2 h of treatment. Prior to this 
time frame, a higher percentage of Cy3 positive cells was seen with sLDH (Figure 5-11A). 
The mean Cy3 fluorescence intensity of cells treated with sLDH was twice that of cells 
treated with L-LDH after 1-8 h of incubation (Figure 5-11B), which indicates that sLDH is 
able to transport twice the load of DNA as L-LDH, at this mass ratio. This observation 
appears to be consistent with the following reports: more rapid internalisation of smaller 
DNA/PEI complexes by K562 cells,65 and smaller PLGA NPs by COS-7 and HEK-293 
cells.66  
5.4 Discussion 
The ease by which therapeutic nanoparticles (e.g. gene-carrier systems) are taken up by 
their target cell population will directly impact on quantifiable outcomes which ultimately 
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dictate their ‘efficiency’, such as the rate and intensity of transfection/fluorescence 
measured across a population of cells. With this in mind, the key concepts underlying this 
work presented here aimed to explore and decipher the effects of the LDH particle size, 
LDH particle number concentration and dye/gene loading by LDH on cellular delivery 
efficiency, using sLDH and L-LDH as our key NP comparators.  
5.4.1 Effect of LDH-NP size on cellular delivery efficiency  
To specifically examine the effect of LDH particle size on delivery efficiency, we fixed the 
particle number concentration of either sLDH or L-LDH particles. Since each L-LDH-FITC 
particle (90 nm) is about 5 times (903/543 = 4.6) larger than each sLDH-FITC particle (54 
nm) from a volume perspective, we employed 4 µg/mL sLDH-5%FITC and 20 µg/mL L-
LDH-1%FITC to ensure the presence of a similar particle number concentration alongside 
an identical load of FITC in each LDH particle. In such an uptake test, the FITC 
fluorescence intensity observed for each NP type when delivered to a population of cells 
directly reflects the impact of the particle size on uptake by HCT-116 cells.  
Under these ‘identical’ conditions, HCT-116 cells were shown to internalise a similar 
amount of FITC irrespective of whether the vector being used was sLDH or L-LDH (Figure 
5-9). The only subtle difference was that the cellular uptake of sLDH NPs was seen to be 
complete in the first 2 h, while L-LDH NPs showed a steady and continual uptake over up 
to 8 h. Thus, this work shows that the rate of cellular uptake in terms of the particle number 
was comparable for the 54 nm (sLDH) and 90 nm (L-LDH) NPs. It is reported that 
internalisation of NPs less than 200 nm involves clathrin-mediated pathway;17, 18, 67, 68 thus 
sLDH-FITC (~54 nm) and L-LDH-FITC (~90 nm) used in this work entered HCT-116 cells 
through the same pathway. That would be the reason why sLDH-FITC and L-LDH-FITC 
resulted in similar uptake regardless of the particle size difference. This result is consistent 
with recent in vitro and in silico correlation studies where NPs ranging in size from 50-100 
nm were found to be optimal for cellular delivery.35 It is also in partial agreement with a 
cluster of earlier studies where ca. 50 nm NPs were more efficiently internalised by a 
range of cell types.6, 47, 69  
Clearly, the cellular uptake rate of L-LDH from the particle ‘mass’ perspective is about 5 
times that of sLDH as the volume of one L-LDH particle is nearly 5 times that of one sLDH 
particle. This translates to the fact that if sLDH-5%FTIC and L-LDH-5%FITC NPs are 
delivered at an equivalent particle number concentration in cellular uptake studies, the 
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mean FITC fluorescence intensity of HCT 116 cells treated by L-LDH-5%FITC would be 
expectedly 5 times that treated by sLDH-5%FTIC, which is really shown by the data in 
Figure 5-6. The mean fluorescence intensity of cells treated by 10.0-20.0 µg/mL of L-LDH-
5%FITC was truly about 5 times that of cells treated by 2.5-5.0 µg/mL of sLDH-5%FITC, 
where the particle number concentration in the two cases was approximately the same. 
5.4.2 Effect of the LDH particle number concentration on cellular 
delivery efficiency 
As shown in Figure 5-6, the amount of FITC delivered by sLDH remained largely 
unchanged at mass doses ≥ 5.0 µg/mL, while it increased substantially at the lower mass 
dose range of 1.4 to 5.0 µg/mL. Similarly, the amount of FITC delivered by L-LDH 
increased steadily at a mass dose from 1.4 to 20.0 µg/mL while the increase was minimal 
from 10.0 to 20.0 µg/mL (Figure 5-6). It appears that cellular uptake of NPs is dose 
dependent below a critical mass concentration, while cellular uptake of NPs reaches a 
plateau at or beyond the critical mass concentration. In the current two cases, the critical 
mass concentration of sLDH and L-LDH is in the region of 5 and 20 µg/mL, respectively. 
Interestingly, the corresponding critical particle number concentration in these two cases is 
very similar, at approximately 1.0×1010 particle/mL, which is also supported by the data 
shown in Figure 5-12. The uptake curves are quite similar for sLDH and L-LDH NPs, with a 
similar critical particle number concentration. Clearly, cellular uptake in terms of the LDH 
particle number is almost linearly dependent on the particle number concentration below 
the critical number concentration (1.0×1010 particle/mL). Beyond this critical value, cellular 
uptake does not improve. Chithrani et al.6 have also reported dose-dependent 
phenomena, and moreover, their critical NP number concentration was estimated to be 
0.3×1010 number/mL for 50 nm Au NPs based on the data provided, which is in close 
agreement to our critical number concentration. Of course, the critical number 
concentration of NPs could also be dependent on the cell type and confluency.  
As depicted in Figure 5-8B, the amount of FITC delivered by L-LDH was approximately 
twice that of sLDH after incubation for 1-8 h at the same mass concentration (10 µg/mL). 
From this we can infer that sLDH particle number taken up by HCT-116 cells was about 
2.5 times that of L-LDH, although the number concentration of sLDH particles was 5 times 
that of L-LDH particles. This uptake rate of sLDH in terms of the particle number is less 
than that expected (5 times), which could be due to the fact that the mass concentration of 
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sLDH (10 µg/mL) is beyond the critical mass concentration value (5 µg/mL) while that of L-
LDH is below. Therefore, the rate of cellular uptake of L-LDH is relatively slower in this 
instance. 
 
Figure 5-12 Replot of normalised particle number concentration and particle number taken 
up by cells based on the data in Figure 5-6, including sLDH and L-LDH. 
5.4.3 Effect of surface/internal-bulk loading on cellular delivery 
efficiency 
The cellular delivery efficiency can be also determined by the manner of loading on/into 
the respective NPs. For example, the amount of DNA-Cy3 delivered by sLDHs was 2-3 
times that delivered by L-LDH (Figure 5-11B). This is in sharp contrast with the results in 
Figure 5-8B where the amount of FITC delivered by sLDH was 2 times less than that 
delivered by L-LDH, which reflects the effect of loading style. It is important to note that 
DNA was loaded onto LDH in a manner different from FITC, where FITC was intercalated 
between the interlayers (bulk way), but DNA predominantly adsorbed onto the surface of 
LDH NPs (surface way). Due to the differences in loading sites on the NP, FITC loading 
could be controlled through percentage of interlayer anion exchange and correlated to the 
LDH NP volume, while DNA loading amount was correlated to the LDH surface area.  
At the equivalent mass concentration, sLDH with the Z-average size of 40 nm has a 
surface area 2.5 times that of L-LDH with the Z-average diameter size of 100 nm. From a 
loading perspective, this means that sLDH is able to carry 2.5 times the load of DNA as 
that of L-LDH, at the equivalent mass concentration. This may explain why sLDH bound 
almost all DNA at the LDH:DNA mass ratio of 2:1 (Figure 5-3A), while a mass ratio of 5:1 
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was necessary in the case of L-LDH (Figure 5-3B). This may further reflect that the 
contribution of unassociated DNA at the mass ratio of 5:1 was much lower from sLDH 
(∼10%) than from L-LDH (∼50%) in the culture media (Figure 5-4A and Figure 5-4B). 
Cebrián et al.70 also found 6 nm PEI-coated Au NPs can load higher quantities of DNA 
than equivalent mass of 70 nm Au-PEI NPs because of larger external surface area per 
unit mass. The incomplete complexation of DNA-Cy3 observed with L-LDH at 5:1 in 
culture media would be expected to reduce the cellular delivery of DNA-Cy3 to 50% of that 
using sLDH at the same particle number concentration.  
Aside from the effect of incomplete complexation, the observed difference in the delivery 
efficiency of DNA-Cy3 may largely be attributed to LDH particle number concentration 
changes. Here, as the L-LDH particle number concentration (1.4 and 11 µg/mL) was well 
below the critical value, cellular uptake of DNA-Cy3 would increase in proportion to the 
particle number concentration. In comparison, sLDH NP number concentration at 1.4 
µg/mL is below the critical value while 11 µg/mL is well over the critical value, so cellular 
uptake would increase less than in a proportional manner. This understanding, together 
with the loading yield, goes some way in explaining why the amount of DNA-Cy3 delivered 
by sLDH was 10-15 times higher than that of L-LDH at the mass ratio of 5:1, decreasing to 
about 2-3 times higher at the mass ratio of 40:1 (Figure 5-10B and Figure 5-11B).  
Figure 5-13 illustrates the relatively particle sizes and particle concentrations for small and 
large LDH carrying FITC and DNA-Cy3. A and B exhibit same mass concentrations of 
small and large LDH carrying same percentages of FITC. C and D show same particle 
concentrations of small and large LDH carrying same amount of FITC in each 
nanoparticle. E and F are small and large LDH carrying DNA-Cy3 at the same mass ratios 
and mass concentrations.  
5.5 Conclusions 
The cellular uptake of LDH NPs is highly dependent on its particle number concentration 
regardless of particle size in the range of 40 to 100 nm. Under the critical particle number 
concentration, cellular uptake was in linear proportion to the particle number concentration, 
while above this critical value, the cellular uptake was not further improved. This research 
further found that the size of sheet-like LDH particles in the range of 40-100 nm could not 
significantly affect the cellular uptake in terms of the particle number, and that the surface 
loading capacity of LDH NPs may significantly affect the delivery efficiency. 
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Figure 5-13 Schematic illustration of small and large LDH NPs carrying FITC and DNA 
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Abstract 
The various classes of gene delivery vector possess distinct advantages and 
disadvantages, each of which impacts on cargo loading, delivery, and ultimately its 
function. With this in mind herein we report on a small layered double hydroxide (sLDH)-
liposome composite system, drawing upon the salient features of LDH and liposome 
classes of vectors, while avoiding their inherent shortfalls when used independently. 
sLDH-liposome composites were prepared by the hydration of freeze-dried matrix method. 
These composite systems, with a Z-average size of ≈ 200 nm exhibited low cytotoxicity 
and demonstrated good suspension stability both in water and cell culture medium after 
rehydration. Our studies demonstrate that short dsDNAs/ssDNAs were completely bound 
and protected in the composite system at an sLDH:DNA mass ratio of 20:1, regardless of 
the approach to loading DNA . This composite system delivered DNA to HCT-116 cells 
with ≈ 3-fold greater efficiency, when compared to sLDH alone. Our findings point towards 
the sLDH-liposome composite system being an effective and biocompatible gene delivery 
system. 
Chapter 6 Enhanced Cellular Delivery and Biocompatibility of a small Layered Double Hydroxide-liposome 
Composite System 
120 
6.1 Introduction 
Gene therapy aims to use genetic materials, namely DNA or RNA as a therapeutic; this 
approach is expected to lead to effective treatment of a wide range of disorders of genetic 
origin, most of which are not amenable to curative therapy using conventional ‘small 
molecule’ agents.1, 2 A growing body of evidence points towards the promise of gene 
therapy as an effective means of treating cancers, as well as genetic and 
neurodegenerative diseases.3, 4 That said success of gene therapy trials relies heavily on 
access to safe and efficient vectors that are able to overcome the various extra- and 
intracellular barriers faced by genetic materials.5-8 
Layered double hydroxides (LDHs) otherwise known as anionic clays are either sourced 
naturally in the form of minerals, or can be synthesised with precise composition and 
particle size homogeneity.9-12 Here, magnesium-aluminium-based LDHs (MgAl-LDH) have 
proved to be excellent gene delivery vehicles, given their intrinsically low cytotoxicity, good 
biocompatibility, well-defined particle size, and cationic surface properties.13-20 The 
positively charged surface of LDH nanoparticles (NPs) allows ready adsorption of 
negatively charged (genetic) materials, driven by electrostatic attraction, a phenomenon 
that leads to cargo being protected from degradation by ubiquitous enzymes, while the net 
cationic charge of LDH-gene complexes facilitates cellular internalisation. Once 
internalised, the gradual dissolution of LDH NPs in the acidifying conditions of the 
endosome results in sustained/controlled release of payload, which in turn raises the 
osmotic pressure in the endosome, and leads to an influx of water, causing swelling and 
finally rupture of endosomal vesicles.21, 22 Once the LDH-gene complexes enter the cytosol 
the LDH system is rapidly disassembled, with the Mg and Al ions eliminated through an 
abundance of membrane-based ion channels. A major drawback to the use of LDH is the 
mass aggregation of LDH NPs resulting from interaction with serum proteins abundant in 
the systemic circulation, a feature which has prevented the wider application of LDH as an 
in vivo compatible gene vector.  
Separately, liposomes have long been trialled and accepted as effective drug/gene 
vectors, given their similarities with the cell membrane, both in structure and composition. 
23 Moreover, the surface of PEGylated liposomes has been readily modified with specific 
ligands for targeted delivery.24-27 However, a rate-limiting step with many non-viral vectors, 
including PEGylated liposomes, is their inability to escape endosomes in a timely manner. 
Hence, researchers have dedicated their efforts to preparing PEGylated liposomes 
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encompassing various fusogenic lipids (e.g. DOPE), and pH-sensitive polymers, such as 
polyethylenimine (PEI) to improve endosomal escape and payload release properties.28, 29 
More recently, lipid-coated hybrid nanoparticles (NPs), such as polymeric NPs, 
mesoporous silica NPs, and calcium phosphate NPs have found a place in combination 
therapy, where attempts are being made to enhance therapeutic efficacy while reducing 
drug resistance and side effects. Such hybrid systems aim to merge the beneficial features 
from both vectors into one nano-carrier, while mitigating their individual drawbacks.26, 30-34 
These findings motivated us to design a new composite system, comprising of LDH and 
liposomes, one that would synergistically enhance the colloidal stability and delivery 
efficiency with reduced side effects. We demonstrated that our novel LDH-liposome 
composite system possesses good colloidal stability and high rate of gene transfection 
with consistent dimensions in the low nanometer size range. 
6.2 Experimental 
6.2.1 Preparation of LDH NPs and LDH-liposome composites 
Small LDH (sLDH) and large LDH (L-LDH) NPs were prepared as reported earlier.35, 36 
The LDH-liposome composite system was prepared by the hydration of freeze-dried matrix 
(HFDM) method, with slight modifications. The minor deviation from the published37-40 
method involved using 30% v/v tertiary butyl alcohol (TBA), as opposed to 50% v/v TBA.41 
Typically, 70 µL of 400 µg/mL sLDH suspension is mixed with 70 µL of 95 mg/mL sucrose 
solution, followed by further mixing with 60 µL of 450 µg/mL EPC (chicken egg-derived L-
α-lysophosphatidylcholine). The resulting clear TBA/water/EPC three phase mixture was 
then snap-frozen in dry ice, followed by freeze-drying for 24 h (Christ Alpha 2-4 LD). 
Finally, the freeze-dried matrix was hydrated with 50-200 µL water and stood at room 
temperature for 10 min.  
6.2.2 Incorporation of DNA into LDH-liposome composite 
The complexation of DNA with our LDH-liposome composite was trialed using three 
different approaches, denoted as ‘LDH-DNA-liposome’, ‘LDH-liposome-DNA’, and ‘LDH-
liposome+DNA’. As depicted in Scheme 1 and elaborated on here, the ‘LDH-DNA-
liposome’ formulation involved first complexing DNA with LDH in a sucrose solution, 
followed by mixing in the EPC in TBA solution, then freeze-drying and hydrating the 
lyophilisate. Similarly, for the ‘LDH-liposome-DNA’ formulation DNA was added to a LDH 
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suspension containing EPC in TBA, with similar post-treatment. Finally, for ‘LDH-
liposome+DNA’ we first prepared the LDH-liposome composite with DNA added directly to 
the nanosuspension.  
Scheme 1. Sequential schematic outlining the preparation of various composite LDH-
liposomal formulations (coloured box widths indicative of the relative volumes employed).  
 
 
6.2.3 Suspension stability test 
All particle size distributions were determined by dynamic light scattering (DLS, Zetasizer 
Nano ZS, Malvern Instruments) where LDH, LDH-DNA, LDH-liposome, and LDH-liposome 
with DNA suspensions were diluted with water at a volume ratio of 1:1 before 
measurement. For their size distribution in cell culture media, they were diluted with 
complete cell culture media (10% v/v of fetal bovine serum mixed with Dulbecco’s Modified 
Eagle Medium (DMEM, with L-glutamine and 4.5 g/L of glucose) at volume ratio of 1:1.  
6.2.4 Agarose gel electrophoresis  
The dsDNA loaded with LDH NPs and LDH-liposome composites were assessed by 
agarose gel electrophoresis. A 2.5% agarose  gel with Gel-Red stain was made and then 
dsDNA bound with LDH NPs/LDH-liposome composites were loaded in the wells. For each 
well, 260 ng dsDNA was used. Gel was imaged by a Bio-Rad imaging system after 
running at 90 V for 45 min in TBE (Tris/Borate/EDTA) buffer. 
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6.2.5 Cell viability 
Human colon cancer HCT-116 cells were seeded in 96-well plates at a density of 2000 
cells per well in 200 µL of cell culture media. After 24 h of incubation, cell culture media 
was replaced by 200 µL of fresh media with desired concentration of LDH or LDH-
liposome NPs. After 48, and 72 h further incubation, 20 µL of MTT reagent (5 mg/mL in 
PBS buffer) was added, followed by 2-4 h of incubation (dependent on cell density). Next, 
the cell culture media was discarded, and 50 µL of DMSO (dimethyl sulfoxide) was added 
to each well, followed by 10 min of incubation. Absorbance was read using a plate reader 
at 540 nm after 1 min of orbital shaking. A negative control group (only cell culture media, 
without cells) was used as background. A group without adding NPs was used as control. 
The cell viability was normalised to control. The experiments were conducted for at least 
two batches in triplicate. Data are presented as mean ± SEM (standard error of the mean). 
Two-way ANOVA was used to assess the statistical significance (commercial transfection 
reagent Oligofectamine™ as control group).  
6.2.6 Cellular uptake 
HCT-116 cells were seeded in 6-well plates at a density of 1×105 cells per well in 2 mL 
complete cell culture media. After 24 h of incubation, cell culture media was replaced with 
1 mL of fresh media containing desired concentration of LDH-DNA-Cy3 NPs (single 
stranded DNA, 21 base, labeled with Cy3) or LDH-liposomes with DNA-Cy3 NPs (20 nM 
DNA). After 4 h of further incubation, the culture media was removed; cells were washed 
twice with PBS buffer and then detached from the plates by trypsin-EDTA. The cells were 
washed twice with PBS buffer and then fixed in a certain volume of 2% PFA 
(paraformaldehyde) before measurement by flow cytometry (BD Accuri™ C6 Flow 
Cytometer System, band pass filter 585/40 was used, 10,000 cells were counted). All 
treatments were performed for three different batches in duplicate. Data are presented as 
the mean ± SEM. Two-way ANOVA was used to assess the statistical significance. 
****p<0.0001.  
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6.3 Results and discussion 
6.3.1 sLDH-liposome composite formation 
As shown in Figure 6-1A, sLDH possesses a narrow particle size distribution in the range 
of 10 to 100 nm with a Z-average size of ∼40 nm. L-LDH NPs have a particle size in the 
range of 20 to 200 nm with Z-average size of ~100 nm (data not shown). After mixing with 
sucrose solution, the LDH suspension particle size increased marginally due to the 
viscosity of the sucrose solution (Figure 6-1A and Figure 6-2A). While in a homogeneous 
TBA/water/EPC three phase mixture, the Z-average particle size increased considerably to 
∼200 nm, indicative of the formation of lipidic micelles (Figure 6-1A and Figure 6-2B). 
 
Figure 6-1 Particle size distribution of sLDH in various mixtures (A); Blank liposome and 
sLDH-liposome prepared by the hydration of freeze-dried matrix (HFDM) method (B). 
Upon cooling TBA present within the core of micelles freezes first, given its relatively high 
freezing point (25.5 °C), this in turn freezes the lipid molecules surrounding the TBA core. 
The water phase freezes next, albeit more gradually due to the presence of sucrose and 
its high concentration, which further assists with more uniform distribution of LDH-payload 
in the water phase of the mixture (Figure 6-2C).40 
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Figure 6-2 Schematic diagram of proposed sLDH-liposome composite formation by the 
HFDM method (for clarity, sucrose is not shown). 
Water and TBA are removed completely during the next freeze drying step. During this 
process the lipid molecules are expected to re-arrange themselves, forming fragments of 
lipid bilayers, while sucrose serves to further stabilise these transient structures (Figure 
6-2D). Upon hydration, the lipid bilayer fragments spontaneously assemble and seal, 
forming liposomes (Figure 6-2E and F). Due to the relatively small size of sLDH NPs (~40 
nm) compared to the forming liposomes, a proportion of the NPs are encapsulated in the 
vesicles during lipid-fragment self-assembly into liposomes, although one can indeed 
expect some sLDH NPs to escape encapsulation (Figure 6-2F). In contrast, when 
considering this process from the perspective of L-LDH NPs, and their capture into forming 
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liposomes (Figure 6-2F), one would expect significant challenges, stemming from the 
considerably larger (~100 nm) size of L-LDH (c.f. sLDH), and so they are deemed to be 
less amenable to composite particle formation.  
The process leading to formation of sLDH-liposome composite NPs prepared by the 
HFDM method is illustrated in Figure 6-2, with the particle size distribution of blank 
liposome and sLDH-liposome shown in Figure 6-1B. When comparing particle size, the 
sLDH-liposome composite with a Z-average size of ~240 nm was found to be greater than 
blank liposome (~200 nm); this difference may be attributed to the adsorption of sLDH NPs 
onto the surface of liposomal vesicles (as shown in Figure 6-2F), and this could well prove 
advantageous from an endosomal escape perspective (discussed later). Another reason 
for the particle size difference could be due to the addition of sLDH which affects the 
formation of liposome structure or the liposome size by encapsulation of sLDH NPs.  
6.3.2 Composite stability 
Figure 6-3A shows the particle sizes of sLDH and sLDH-liposome formulations loaded with 
dsDNA in water and in cell culture media at a dsDNA concentration of 10 µg/mL. sLDH-
dsDNA has a larger particle size in cell culture media (~90 nm) than in water (~64 nm), 
which can be attributed to the adsorption of serum proteins onto the surface of sLDH NPs. 
In contrast, the sLDH-liposome suspension and sLDH-liposome loaded with dsDNA 
possessed an average particle size between 200-240 nm, which is consistent with the size 
of cationic liposomes loaded with siRNA reported by Wu et al. 37 and this particle size 
range is also appropriate for subsequent cellular uptake. Moreover, this observation 
illustrates that loading dsDNA into the sLDH-liposome composite system does not 
significantly affect composite size. 
In contrast to sLDH, the average particle size of L-LDH-dsDNA composite is smaller in cell 
culture media than in water (Figure 6-3B) due to the adsorption of proteins onto LDH, 
which in turn suppresses aggregation between positively charged LDH NPs and negatively 
charged dsDNA. Similar particle sizes (~200 nm) were observed for L-LDH-liposome 
formulations loaded with dsDNA (at 10 µg/mL), which is suitable for cellular internalisation. 
Given that L-LDH NPs do not associate with or are too large for encapsulation within 
liposomes, and at the equivalent mass concentrations, L-LDH has a much lower particle 
number concentration than sLDH and liposome vesicles, so the L-LDH-liposome particle 
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size would be expected to be smaller than that of the sLDH-liposome composite, which is 
largely attributed to the blank liposome. 
 
Figure 6-3 The Z-average particle sizes of LDH NPs and LDH-liposome formulations 
loaded with dsDNA (dsDNA = 10 µg/mL, the mass ratio LDH:dsDNA = 20:1, EPC:dsDNA 
= 20:1, *MS = medium + serum i.e. complete cell culture medium). 
6.3.3 Cytotoxicity of LDH and LDH-liposome NPs 
LDH and LDH-liposome NPs show negligible cytotoxicity at 72 h even when employing 
artificially larger concentrations (i.e. 100-200 µg/mL, >10 times the practical 
concentration), as shown in Figure 6-4, with > 90% cell viability at 48 h, and > 70% cell 
viability at 72 h at 200 µg/mL of LDH in the systems. In contrast,  transfection reagent 
Oligofectamine™ exhibits significantly higher cytotoxicity at the comparable dose (~45% 
cell viability at 48 h and ~30 % cell viability at 72 h, p<0.0001, and where ‘1’ of 
Oligofectamine™ equals the minimum recommended dose). Consistent with previous 
reports the cytotoxicity of LDH 17, 35 and liposomes composed of neutral lipids 42, 43 show 
moderate levels of cytotoxicity.  
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Figure 6-4 Cell viability of LDH and LDH-liposome NPs (MTT assay, in LDH-Liposome 
formulations LDH:EPC mass ratio = 1:1, transfection reagent Oligofectamine™ was used 
as positive control, 1* = minimum recommended dose of Oligofectamine™) 
6.3.4 Nucleic acid loading 
Figure 6-5A shows the electrophoretic mobility of sLDH-liposome composites in the 
presence of dsDNA. It is evident that sLDH and sLDH-liposome composites completely 
bind dsDNA, irrespective of the dsDNA loading method (sLDH:dsDNA mass ratio = 20:1, 
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Lane 3 to Lane 6), driven by the positively charged property of sLDH NPs, which fully 
immobilises the negatively charged DNA in the wells at this mass ratio. However, neutral 
liposomes (EPC:dsDNA = 20:1, Lane 7) cannot fully retard dsDNA migration in the well. 
This difference reveals, as alluded to earlier, that there are likely to be sLDH NPs residing 
outside the sLDH-liposome composite, which help to immobilise dsDNA in the well (sLDH 
NPs fully associate dsDNA at mass ratio of 5:1, as reported earlier 36), as proposed and 
shown in Figure 6-2F.  
 
Figure 6-5 Electrophoresis mobility of HFDM LDH-liposome composite for dsDNA loading 
(LDH:DNA mass ratio = 20:1, EPC:DNA mass ratio = 20:1)  
L-LDH and L-LDH-liposome yielded similar profiles for dsDNA immobilisation, as shown in 
Figure 6-5B. L-LDH and all L-LDH-liposome formulations can fully complex with dsDNA in 
the wells regardless of the dsDNA loading method (Lane 3 to Lane 6, positively charged L-
LDH NPs can also fully combine with DNA at this mass ratio). This also indicates that L-
LDH NPs are almost entirely residing outside L-LDH-liposome composites, thus allowing 
direct interaction with dsDNA. In addition, the two faintest bands in lane 2 and 7 (Figure 
6-5B) arise from strand dissociation (to ssDNA), which can occur upon extended storage 
of dsDNA. 
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6.3.5 Cellular delivery 
In consideration of the high cellular delivery of DNA using LDH NPs only (~100% of 
positive cells were observed when 40 nM of Cy3-DNA was used with LDH NPs), 20 nM of 
Cy3-DNA was used here to evaluate the cellular uptake differences between LDH and 
LDH-liposome composite.  
 
Figure 6-6 Cellular uptake of DNA-Cy3 by HCT-116 cells at 20 nM DNA, LDH:DNA mass 
ratio = 20:1, EPC:DNA = 20:1, and 4 h incubation. 
Cellular uptake of Cy3-DNA (20 nM) delivered using either LDH or LDH-liposome 
composite after 4 h incubation are shown in Figure 6-6A and B. The LDH-liposome 
composite led to a similar number of Cy3 positive cell population when compared to (s/L-
)LDH alone. Unsurprisingly, the average amount of DNA delivered into each cell by sLDH-
DNA-liposome and sLDH-liposome-DNA was 2.9- and 2.2-fold higher, respectively, when 
compared to that achieved with sLDH alone. In contrast, sLDH-liposome+DNA and 
liposome-DNA gave a lower relative average Cy3 intensity/cell (= Cy3 intensity of Cy3 
positive cells × Cy3 positive cell percentage; the fluorescence of non-Cy3 positive cells 
was disregarded) than sLDH alone. The reason for the latter observation is most likely due 
to the lower loading efficiency of dsDNA into liposomes (Figure 6-5), while for the former 
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this could be due to the competition for internalisation existing between empty sLDH-
liposomes, blank liposomes, and sLDH-DNA NPs, more likely, the encapsulated sLDH 
NPs are redundant in this case.The average Cy3 intensity delivered by L-LDH-liposome 
composites was much lower than that achieved by sLDH-liposome composites (Figure 
6-6B). Moreover, their average Cy3 intensity is very similar in these cases, consistent with 
the idea that L-LDH largely resides outside L-LDH-liposomes, which leads to a similar 
internalisation profile of DNA-Cy3 via L-LDH NPs. 
6.3.6 Why does the sLDH-liposome composite enhance cellular 
delivery? 
sLDH-liposome composites possess improved cellular delivery properties, and this could 
be attributed in part to the encapsulation of sLDH NPs inside liposomal vesicles. Firstly, 
association of sLDH with liposomal vesicles also reduces the risk of aggregation between 
sLDH NPs and serum proteins, thus improving the in-suspension stability of sLDH(-DNA) 
NPs, so that the bioavailability and retention of sLDH-DNA NPs in the cell culture media is 
improved. Other researchers in the field have also related the increased uptake/delivery of 
cell penetrating peptides, micelles-iron oxide NPs and LDH NPs to their greater stability 
under physiological conditions.44-46 Moreover, smaller dimensions of the resulting 
complexes normally leads to rapid, receptor-mediated internalisation, while larger, 
aggregated complexes may show less efficient unspecific uptake through adsorptive 
endocytosis, which is a relatively slower process.47 Furthermore, with improved composite 
suspension stability, the system would be expected to perform well in both suspended and 
adherent cell lines (previously we found transfection of the suspended cell line CHO-S 
using LDH NPs was not very successful, unlike adherent cell lines such as HEK293T, NIH 
3T3, COS-7, and CHO-K1 16).  
Aside from the key driver to internalisation, which is electrostatic interaction between sLDH 
NPs and the glycocalyx present on the surface of cells, another crucial factor driving 
delivery and partitioning is the affinity of phospholipids (from liposomes) for lipids of the 
cell membrane. This can be confirmed by the > 50% of Cy3 positive cell population 
achieved with liposomes, while the DNA delivery efficiency obtained was low, due to the 
poor gene loading capacity (Figure 6-5, lane 7). 
Followed by enhanced cellular uptake, efficient cargo release is also crucial for any 
competent gene delivery vector. The proposed endosomal escape pathway for this sLDH-
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liposome composite is outlined in Figure 6-7.21, 22 Following internalisation of the sLDH-
liposome composite, sLDH NPs which are external to the liposomal vesicles or adsorbed 
onto their surface dissolve gradually under the acidic conditions inside endosomes. This 
results in increased osmotic pressure inside endosomal vesicles, which causes an influx of 
water into endosome, and this then swells the endosome (Figure 6-7A to B). Further 
dissolution of sLDH NPs outside and inside liposomal vesicles leads to even higher 
osmotic pressures and further swelling of liposomal and endosomal vesicles, which finally 
leads to rupture of endosomal and liposomal vesicles and cargo release into the cytoplasm 
(Figure 6-7C). Note that in the case of liposomes, the internalised liposome-DNA 
complexes cannot escape from endosome in a timely manner, which leads to the bulk of 
DNA being degraded in the lysosome. 
 
Figure 6-7 Possible endosomal escape pathway for sLDH-liposome composite 
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6.4 Conclusions 
LDH-liposome composites prepared using the HFDM method possess good particle size 
distribution with Z-average size ~200 nm after hydration, and they are suitable for cellular 
uptake studies. The composite systems are stable in the culture medium with limited 
cytotoxicity observed. More interestingly, the sLDH-liposome system shows higher cellular 
delivery efficiency (2-3 times higher) than sLDH alone, while the L-LDH-liposome 
composite did not exhibit significant differences from L-LDH. The reasons we put forward 
for these observation are that: (1) sLDH can be easily encapsulated in the aqueous core of 
liposome because of its small size; (2) some sLDH NPs could attach to the surface of the 
liposome bilayer, which helps bind and protect DNA, and more importantly, helps its 
escape from the endosome; (3) the hydrophobicity of liposomes may also facilitate their 
cellular uptake. Thus, this research has demonstrated that a carefully engineered 
combination of sLDH and liposome synergises the cellular delivery efficiency, by taking 
advantages of both systems salient features.  
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Chapter 7 Conclusions and Future Directions 
7.1 Conclusions 
The first major contribution of this thesis is the control synthesis of small LDH (sLDH) 
nanoparticles (NPs) by a non-aqueous co-precipitation method. A methanolic solution 
containing magnesium and aluminium nitrate is mixed with sodium hydroxide in methanol, 
followed by removal of side product sodium nitrate and hydrothermal treatment in 
methanol. The collected precipitate is then washed and finally dispersed in water into 
homogeneous sLDH NP suspension. The resultant sLDH NPs possess a Z-average 
diameter particle size in the range of 35 ~ 50 nm with good colloidal stability at room 
temperature for a couple of months. The hydrothermal treatment duration from 0 to 48 h, 
and the hydrothermal treatment temperature from 60 to 100 °C have slightly influenced the 
sLDH particle size, but removal of sodium nitrate before hydrothermal treatment is crucial 
for good dispersion of final sLDH suspension.  
Secondly, this research has observed that the most important factor that affects the 
cellular internalisation rate is the LDH NP number concentration instead of the LDH 
particle size in the range of 35 ~ 100 nm. A critical particle number concentration has been 
deduced for both sLDH and normal LDH (denoted as large LDH, L-LDH in this thesis) 
NPs. Below this value the cellular uptake by human colon cancer (HCT-116) cells is 
proportional to the particle number concentration, but above the value the cellular uptake 
is saturated and cannot be improved further. At the same particle number concentration, 
the cellular uptake profile of sLDH and L-LDH NPs is very similar, indicating that the 
particle internalisation is not substantially affected by the size in the range (35 ~ 100 nm). 
The drug/gene loading style and loading capacity have been also noted to affect the 
efficacy of drug/gene delivery to this cell line.   
Lastly, this research suggests that the hydration of freeze-dried matrix (HFDM) method is 
a proper way to prepare the LDH-liposome composites, although their structure and 
morphology are not clear at the moment; and moreover, the sLDH-liposome composites 
facilitate the cellular uptake significantly. sLDH-liposome composites were firstly attempted 
by the hydration of thin lipid film (HTLF) method, but multilamellar vesicles were obtained 
and pretty low encapsulation was achieved after size reduction by probe sonication or 
extrusion. After preparation using HFDM method, the sLDH-liposome composite 
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suspension has good suspension stability with the Z-average diameter size ~ 200 nm, 
which is suitable for cellular uptake. sLDH-liposome composites are able to transport 2-3 
times more DNA to HCT-116 cells than sLDH only, which could be attributed to synergistic 
combination of sLDH NPs and liposomes. No significant improvement is seen for L-LDH-
liposome composites prepared by the same method, which probably suggests that there is 
no such synergistic combination of L-LDH NPs and liposomes. 
7.2 Future directions  
Enhanced cellular delivery of nucleic acids has been observed for sLDH-liposome 
composites; however, more efforts could be made to further improve this hybrid system, 
such as:  
[1] investigating the mechanisms for sLDH-liposome composite formation, and 
further confirming the hybridisation by encapsulating sLDH NPs inside 
liposomal vesicles or associating sLDH NPs on the surface of liposomes or the 
proportion of encapsulation to association; This understanding will help improve 
the encapsulation efficiency of sLDH in the liposomal vesicles, probably through 
optimisation or development of new method(s) to prepare liposomal 
formulations or other liposomal compositions;  
[2] examining the cellular uptake behaviour and the endosome escape pathway of 
sLDH-liposome composites, which would pave a way to further enhance their 
cellular delivery efficiency; 
[3] modifying liposomes with polyethylene glycol (PEG) for further increasing the 
stability of the composite system and extending its circulation time; linking some 
antibodies or peptides for specific target delivery of genetic therapeutics;  
[4] developing combination therapy for this composite system, for example, using 
LDH to load hydrophilic anionic drugs and genes, and liposomes to carry 
hydrophobic drugs.  
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Appendix Preparation of small Layered Double 
Hydroxide-liposome Composite by Hydration of Thin 
Lipid Film Method 
 
Abstract 
To encapsulate sLDH NPs inside liposomal vesicles to form sLDH-liposome composites, 
commonly used liposome preparation method hydration of thin lipid film (HTLF) was used. 
Micron size of multilamellar vesicles was obtained after hydrated with sLDH suspension 
with encapsulation efficiency up to 30%. Size reduction of liposomal vesicles was done by 
both extrusion and sonication methods, however, sLDH-liposome complexes might easily 
block the filter membrane pores and pretty low amount of sLDH-liposome composites were 
obtained after extrusion, while sonication led to smaller size of liposomal vesicles with low 
encapsulation efficiency. In summary, HTLF method might not be a proper method to 
prepare sLDH-liposome composites with high encapsulation efficiency and good size 
distribution.  
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A1 Introduction about liposome preparation 
There are quite a few methods for making liposomal formulations, such as hydration of thin 
lipid film (HTLF), hydration of freeze-dried matrix (HFDM),1-5 microfluidic jetting,6 reverse 
phase evaporation.7-10 Of them, HTLF is a conventional and easy way to form liposomes. 
However, liposomes made from this method are normally large/giant multi-lamellar 
vesicles because of the stacked lipid bilayers in lipid film state. Therefore, following size 
reduction is always needed. The most commonly used size reduction techniques are 
extrusion11-17 and sonication. Figure A1 shows the schematic diagram for preparing 
liposomes using HTLF method, followed by size reduction via extrusion or sonication.  
 
Figure A1 Preparation of liposomes by HTLF method, followed by size reduction via 
extrusion or sonication; MLV: multilamellar vesicle; LUV: large unilamellar vesicle; SUV: 
small unilamellar vesicle; http://www.avantilipids.com/ 
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Figure A2 shows the extruder used in our lab (Lipex™ Extruder, manufactured by Northern 
Lipids (Vancouver, BC, Canada), has a 10 mL capacity and can be operated over a wide 
range of temperatures when used in combination with a circulating water bath. The quick-
release sample port at the top of the unit allows for the rapid cycling of sample through the 
filters), the particle sizes and polydispersity index (PdI) of liposome suspension, prepared 
by HTLF method, followed by sequential extrusion.  
 
Figure A2 Picture of extruder used (Top) and Z-average particle sizes and polydispersity 
index values of liposomes after extrusion through polycarbonate membrane(Down); for 
each pore size of polycarbonate membrane, liposomes were extruded through 10 times  
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Originally formed liposomes possess sizes in micron range. With extrusion through 800 
nm polycarbonate membrane, the particle sizes reduced rapidly from 3 µm to less than 1 
µm, but the PdI fluctuated and kept above 0.70. Starting from extrusion through 400 nm 
membrane, the vesicle sizes reduced gradually together with PdI, ended with Z-average 
size ~ 350 nm and PdI ~ 0.45. Z-average size of ~ 150 and ~ 110, and PdI of ~ 0.15 and 
0.10 were obtained after sequential extrusion through 200 and 100 nm membranes 10 
times, which implied good sizes of liposomes with narrow size distribution were obtained 
by this method, so called large unilamellar vesicles shown in Figure A1. The final liposome 
vesicle sizes could be well controlled by the membrane used.  
 
Figure A3 Picture of probe sonicator used for reducing liposome size (A), and cryo-TEM 
image of blank liposomes, prepared by HTLF method, size reduced by probe sonication 
(B) 
Figure A3 shows the probe sonicator used in our lab, and the cryo-TEM image of 
liposomes prepared by HTLF method, followed by probe sonication for size reduction. It 
can be seen that after probe sonication, most of liposomes are unilamellar vesicles, but 
the sizes of these vesicles are mainly smaller than 100 nm with majority of them ≤ 30 nm, 
which are so called small unilamellar vesicles as shown in Figure A1.sLDH-liposome 
composite was then attempted by HTLF method. The amount of sLDH encapsulated 
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inside liposomal vesicles or attached on liposome surfaces were characterised by 
centrifugation washing followed by elemental analysis of magnesium and aluminium 
amounts in the final pellet by ICP-AES. Amounts of sLDH in originally formed composite 
suspension (MLVs) and smaller sizes of composites (after size reduction by extrusion or 
sonication) were determined. A range of parameters, such as lipid film thicknesses, 
liposome concentrations, sLDH concentrations were varied to investigate their impact on 
the encapsulation efficiency. 
A2 Encapsulation of sLDH in multilamellar large vesicles 
(MLVs) 
A2.1 Effect of lipid film thickness on encapsulation 
A2.1.1 By changing lipid amount 
About 100, 50 and 20 mg of EPC were dissolved in 5 mL of chloroform in 100 mL of round 
bottom flasks (RBFs), respectively, then chloroform was evaporated by rotary evaporator 
to form thin lipid film. After that, 5 mL of sLDH suspension (7.26 mg/mL) was added for 
rehydration by hand-shaking.  
 
Figure A4 Experimental flowchart for sLDH encapsulation in MLVs (varying lipid amount) 
After the liposome suspension was standing at room temperature for 30 min, 1 mL of the 
sLDH-liposome composite was subjected to centrifugal washing three times by 10 mL of 
DI water at 48,000 g for 15 min to separate free sLDH particles from sLDH-liposome 
composite by dilution effect. Final pellet was digested by 10 mL of nitric acid at 80 °C, and 
then diluted 100 times for ICP-AES test of Mg and Al concentrations. The original sLDH 
suspension used for rehydration was also digested and diluted by 100 times for ICP-AES 
test of Mg and Al concentrations. Encapsulation efficiency of sLDH was calculated from 
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the sLDH amount in composite and the total sLDH amount used for rehydration. The 
experimental flowchart is shown in Figure A4 and the results are listed in Table A1. 
sLDH suspension used for hydration was fixed at 5 mL and 6~7 mg/mL. When the lipid 
amount increased from 20 mg to 100 mg, the sLDH encapsulation efficiency did not 
change much, which meant the lipid to sLDH ratio in the final composite was not affected 
much by liposome concentration.  
Table A1 sLDH encapsulated in liposomal vesicles under different liposome 
concentrations-1 (varying lipid amounts) 
Batch 
Lipid 
amount 
Mg in 
composite 
Al in 
composite 
Mg in LDH 
for 
rehydration 
Al in LDH for 
rehydration 
Encapsulation 
by Mg 
Encapsulation 
by Al 
 mg mg mg mg mg % % 
1 101 0.56 0.29 
8.86 2.78 
6.32 10.3 
2 52.0 0.48 0.23 5.36 8.09 
3 22.5 0.55 0.27 6.15 9.53 
A2.1.2 By changing round bottom flask size 
Three sizes of RBFs, 100, 50 and 20 mL, were used to form thin lipid film by rotary 
evaporator, where about 50 mg of EPC was dissolved in 5 mL of chloroform, respectively. 
After that, 5 mL of sLDH suspension (~24 mg/mL) was added for rehydration by hand-
shaking. The following treatments were the same as in A2.1.1 By changing lipid amount 
and the results results are shown in Table A2.  
No matter changing lipid amounts in certain volume of round bottom flask or changing 
round bottom flask volume while using certain amount of lipid, it seems no significant 
difference for the encapsulation efficiency; therefore it appears that the thickness of lipid 
film does not affect the encapsulation efficiency much. 
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Table A2 sLDH encapsulated in liposomal vesicles under different liposome 
concentrations-2 (varying round bottom flask sizes) 
Batch 
RBF 
volume 
Mg in 
composite 
Al in 
composite 
Mg in LDH 
for 
rehydration 
Al in LDH for 
rehydration 
Encapsulation 
by Mg 
Encapsulation 
by Al 
 mL mg mg mg mg % % 
1 100 6.50 2.50 
31.0 12.0 
21.0 20.8 
2 50.0 5.50 2.30 17.7 19.2 
3 20.0 5.50 2.30 17.7 19.2 
A2.2 Effect of liposome concentration on encapsulation  
Effect of liposome concentration on the encapsulation efficiency of sLDH NPs in liposomal 
vesicles were investigated in this project by changing sLDH suspension volume used. 
Considering concentration dependent encapsulation of silica nanoparticles in the 
polymersomes reported,18 two concentrations of sLDH suspension were used in this 
project.  
A2.2.1 sLDH concentration of 22 mg/mL 
Three batches of thin lipid film were prepared from about 50 mg of EPC in 5 mL of 
chloroform by rotary evaporator. Then 2, 5 and 10 mL of sLDH suspension (22.1 mg/mL) 
were added for rehydration, respectively. The results are listed in Table A3.  
It appears that the encapsulation efficiency of sLDH in composites decreased with larger 
volume of sLDH suspension used, however, 5 mL sLDH led to the highest absolute sLDH 
amounts in the composites, which might imply a proper sLDH/lipid ratio or hydration 
volume for encapsulation. 
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Table A3 sLDH encapsulated in MLVs when different volumes of sLDH suspension used 
for hydration (sLDH concentration 22 mg/mL) 
Batch 
sLDH 
volume 
Mg in 
composite 
Al in 
composite 
Mg in LDH 
for 
rehydration 
Al in LDH for 
rehydration 
Encapsulation 
by Mg 
Encapsulation 
by Al 
 mL mg mg mg mg % % 
1 2.00 2.16 0.81 10.3 3.56 21.0 22.6 
2 5.00 4.84 2.11 25.7 8.89 18.8 23.7 
3 10.0 3.82 1.50 51.4 17.8 7.43 8.42 
A2.2.2 sLDH concentration of 12 mg/mL 
Three batches of thin lipid film were prepared from about 50 mg of EPC in 5 mL of 
chloroform by rotary evaporator. Then 2, 5 and 10 mL of sLDH suspension (12 mg/mL) 
were added for rehydration, respectively. The results are shown in Table A4.  
Table A4 encapsulated in MLVs when different volumes of sLDH suspension used for 
hydration (sLDH concentration 12 mg/mL) 
Batch 
sLDH 
volume 
Mg in 
composite 
Al in 
composite 
Mg in LDH 
for 
rehydration 
Al in LDH for 
rehydration 
Encapsulation 
by Mg 
Encapsulation 
by Al 
 mL mg mg mg mg % % 
1 2.00 1.80 0.74 6.00 2.40 30.0 30.8 
2 5.00 3.30 1.40 15.0 6.00 22.0 23.3 
3 10.0 4.20 1.70 30.0 12.0 14.0 14.2 
Similar to 22 mg/mL sLDH suspension used, encapsulation efficiency of sLDH in 
composites decreased with the sLDH volume used for rehydration, and 2 mL of 12 mg/mL 
sLDH resulted in highest encapsulation ~ 30%. However, the final sLDH to lipid ratio in the 
purified composite increased with sLDH volume used for rehydration from 0.21:1 (2 mL 
sLDH) to 0.48:1 (10mL sLDH). 
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A2.3 Effect of sLDH concentration on encapsulation 
Three batches of thin lipid film were prepared from about 50 mg of egg PC in 5 mL of 
chloroform by rotary evaporator. Then 5 mL of sLDH suspension with concentration of ~6, 
12, 24 mg/mL were added for rehydration, respectively. The results are listed in Table A5.  
Table A5 sLDH encapsulated in MLVs when different concentration of sLDH used for 
hydration 
Batch 
sLDH 
conc. 
Mg in 
composite 
Al in 
composite 
Mg in LDH 
for 
rehydration 
Al in LDH for 
rehydration 
Encapsulation 
by Mg 
Encapsulation 
by Al 
 mg/mL mg mg mg mg % % 
1 6.00 1.50 0.60 7.50 3.00 20.0 20.0 
2 12.0 3.50 1.40 15.0 6.00 23.3 23.3 
3 24.0 7.30 3.00 31.0 12.0 23.5 25.0 
It seems that sLDH concentration has marginal influence on encapsulation efficiency, 
although the encapsulation efficiency improved a little with sLDH concentration increase. 
However, sLDH to lipid ratio in the final composite varied a lot, from 0.17:1 (sLDH 
concentration ~ 6 mg/mL) to 0.40:1 (sLDH concentration ~ 12 mg/mL), 0.83:1 (sLDH 
concentration ~ 24 mg/mL)  
A2.4 Negatively charged lipid was included 
To further improve the encapsulation of positively charged sLDH NPs in liposomal 
vesicles,  10% (molar ratio) of negatively charged lipid (DOPA, 1,2-dioleoyl-sn-glycero-3-
phosphate (sodium salt), C39H72O8PNa) was included for liposomal formulation, 
encapsulation efficiency of sLDH in MLVs was significantly improved from less than 30% 
to around 80% (78.57% by Mg and 80.17% by Al), which was probably due to the strong 
electrostatic interaction between negatively charged DOPA and positively charged sLDH 
particles, which caused unfavourable large aggregates.  
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A3 Encapsulation of sLDH in small unilamellar vesicles (SUVs) 
A3.1 MLVs to SUVs by extrusion 
About 50 mg of EPC was dissolved in 5 mL of chloroform to form thin lipid film by rotary 
evaporator, then 10 mL of sLDH suspension (~24 mg/mL) was added to each RBF for 
rehydration. After liposome suspensions were standing at room temperature for 30 min, 
the suspension was subjected to 10 cycles of freezing-thawing treatment before extrusion 
through polycarbonate filter membranes 800, 400 and 200 nm successively. The 
composite suspensions, before and after freezing-thawing treatment, after each extrusion, 
were subjected to 3 times of centrifugation at 48,000 g for 15 min, and then all the final 
pellets and post-extrusion suspension were digested and diluted for ICP-AES test of Mg 
and Al concentrations. Original sLDH suspension used for rehydration was also digested 
and diluted for ICP-AES test of Mg and Al concentrations. Encapsulation efficiency was 
calculated from the sLDH amount remained in composite and total sLDH amount used for 
rehydration, and then listed in Figure A5.  
 
Figure A5 Encapsulation of sLDH in sLDH-liposome composites after sequential extrusion 
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After freezing-thawing treatment, encapsulation of sLDH in the composite increased to 
around 80 % from 13.6 %, which confirmed the complexation of sLDH with lipids during 
freezing-thawing process with time. Similar to the results before, encapsulation after 
extrusion was lower than 0.5 %, especially after suspensions were subjected to 3 times of 
centrifugal washing, which also confirmed the complexation of sLDH with lipids during 
freezing-thawing cycles 
A3.2 MLVs to SUVs by probe sonication 
About 50 mg of EPC was dissolved in 5 mL of chloroform for forming thin lipid film, then 5 
mL of sLDH-1% FITC was added for hydration. After the suspension was standing at room 
temperature for 30 min, the suspension was treated by probe sonication (100% amplitude) 
for 27 min in a mode of 20 s ON 20 s OFF to avoid suspension overheat. The liposomal 
vesicle size is 110 to 130 nm in diameter according to Z-average. Then 1 mL of the above 
suspension was centrifuged and washed by 1 mL of deionised water for 3 times at 16,000 
g for 10 min. The supernatant after centrifugation were supernatant 1, 2, 3 and 4 
respectively. The final pellet was redispersed in 1 mL of DI water. All the supernatants and 
final pellet dispersion were analysed by UV-vis for FITC concentration (10% of Trition X-
100 was added to final Triton X-100 concentration of 1% to break down the liposomal 
vesicle structure). The percentages of FITC in each partition indicated the sLDH particle 
distribution in each partition.  
Table A6 Size distribution of liposome-sLDH-FITC particles 
Sample Name Z-Ave PdI Intensity Mean Number Mean Volume Mean 
 
d.nm 
 
d.nm d.nm d.nm 
liposome-sLDH-FITC_15 min sonication 185 0.419 300 45.9 275 
liposome-sLDH-FITC_27 min sonication 118 0.242 200 50.2 293 
liposome-sLDH-FITC_pellet redispersion 205 0.268 269 112 306 
The size distribution of liposome-sLDH-FITC particles is shown in Table A6. After 27 min 
of probe sonication, the sLDH-FITC-liposome composites with free sLDH-FITC NPs show 
good size distribution with Z-average size around 120 nm. After the suspension was 
subjected to ce 
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ntrifugal washing, the redispersed pellet (supposed to only contain sLDH-FITC-liposome 
composites) also possessed a good size distribution with Z-average size ~ 200 nm. 
The FITC indicated sLDH distribution in sLDH-liposome composites was shown in Table 
A7. More than 70% of FITC was found in the first supernatant separated from sLDH-
liposome suspension, which meant most of the sLDH-FITC NPs were free in the 
suspension, without encapsulated inside liposomal vesicles or attached on the liposomal 
surfaces. While less and less FITC was detected in the following washing supernatant, 
7%-11% in second supernatant, 4%-6% in third supernatant, ~ 2% in fourth supernatant, 
which might be sLDH-FITC NPs that attached on the surface of liposomal vesicles, so that 
being washed away gradually. The sLDH-FITC left in the final pellet was ~ 10% (indicated 
by FITC), which implied ~ 10% of sLDH-FITC NPs were encapsulated inside the liposomal 
vesicles; this was partly consistent with the results obtained from ICP-AES test of Mg and 
Al concentrations. 
Table A7 sLDH distribution in composite sLDH-liposome system and sLDH encapsulated 
in SUVs, characterised by FITC using UV-vis spectrometer 
 sLDH % 
 Batch 1 Batch 2 
Supernatant 1 71.7 76.7 
Supernatant 2 7.39 10.5 
Supernatant 3 4.40 5.38 
Supernatant 4 1.89 2.08 
Final pellet 8.89 12.2 
Total recovery 94.3 107 
Figure A6 shows the cryo-TEM image of sLDH-liposome composites by hydration of thin 
lipid film (HTLF) method. Few sLDH NPs were seen located inside the liposomal vesicles 
(which were really encapsulated inside the vesicles or in small probability, in the front or 
behind the liposomal vesicles), but most of them were attaching on the surface of 
liposomal vesicles or even piled with liposomal vesicles deformed in between the layers. 
Many sLDH NPs were observed like standing on the grid as a side view, which is because 
the grid was upright when sample was dropped on it, and the sLDH NPs tended to 
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horizonal plate status/shape in the suspension. This is the reason why we always see top 
view of LDH NPs with hexagonol morphology under normal TEM. 
 
Figure A6 Cryo-TEM image of sLDH-liposome composite by HTLF method, composites 
washed by centrifugation, followed by size reduction via probe sonication 
A4 Summary 
sLDH-liposome composites were attempted by hydration of thin lipid film (HTLF) method. 
Encapsulation of sLDH NPs up to 30% were obtained, and the encapsulation was 
dependent on sLDH suspension volume and concentration used. However, commonly 
used extrusion is not a proper way to reduce the size of liposomal vesicles from 
multilamellar vesicles to unilamellar vesicles, because the sLDH-liposome complexes 
easily block the pores of filter membranes, especially under high pressure. Probe 
sonication is an effective and efficient size reduction method, but small vesicles were 
normally obtained, along with low encapsulation of sLDH NPs.  
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